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Luteinizing hormone (LH) and chorionic gonadotropin (CG) are glycoproteins fundamental 
for sexual development and reproduction. Since they act on the same receptor (LHCGR), 
there is a general consensus that LH and hCG are equivalent. However, separate evolution of 
LHβ and hCGβ subunits occurred in primates, resulting in two molecules sharing ~85% 
identity and regulating different physiological events. Pituitary, pulsatile LH production 
results in a ~90 min half-life molecule targeting the gonads, to regulate gametogenesis and 
androgen synthesis. Trophoblast hCG, the “pregnancy hormone”, exists in several isoforms 
and glycosylation variants with long half-lives (hours), angiogenic potential, and acts on 
luteinized ovarian cells as a progestational. The different molecular features of LH and hCG 
lead to hormone-specific LHCGR binding and intracellular signaling cascades. In ovarian 
cells, LH action is preferentially exerted through kinases, pERK1/2 and pAKT, resulting in 
irreplaceable proliferative/anti-apoptotic signals and partial agonism on progesterone 
production in vitro. In contrast, hCG displays notable cAMP/PKA-mediated steroidogenic 
and pro-apoptotic potential, which is masked by estrogen action in vivo. In vitro data are 
confirmed by large dataset from assisted reproduction, since the steroidogenic potential of 
hCG positively impacts on the number of retrieved oocytes, while LH impacts pregnancy rate 
(per oocyte number). Interestingly, Leydig cell in vitro exposure to hCG results in 
qualitatively similar cAMP/PKA and pERK1/2 activation as compared to LH, as well as 
testosterone. The supposed equivalence of LH and hCG is debunked by such data 
highlighting their sex-specific functions, thus deeming it an oversight caused by incomplete 
understanding of clinical data. 
LH and hCG regulate specific physiological events. Indeed, recent in vitro and in vivo data 
demonstrated that LH and hCG can not be used equivalently for clinical treatments. 
Essential points 
In the last decade, the two hormones LH and hCG were considered equivalent since they bind the 
same receptor, clearly activating the classically known cAMP/PKA steroidogenic pathway. 
Clinical evidences of small or undetectable different outcomes between LH or hCG usage 
underlined this concept. 
Recent in vitro studies demonstrated that intracellular signaling, downstream events and cell fate 
are specifically mediated by LH and hCG. 
LH activates preferentially ERK1/2- and AKT-dependent proliferative signals, while hCG is mainly 
progestinic, supporting the physiological roles of the two hormones. 
In the last twenty years, studies comparing the use of commercial LH and hCG preparations in 
reproductive medicine provided clinical evidence of the differences observed in vitro, confirming in 
vitro results. 
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These data indicate that LH and hCG have unreplaceable roles, overthrewing the old concept that 
they are equivalent and revisiting the basis on which clinicians decide the application of these 
hormones. 
I.  Introduction 
Luteinizing hormone (LH) and the primate-specific chorionic gonadotropin (CG) are 
glycoproteins fundamental for sexual development and reproduction. Both hormones have 
been considered equivalent for long time, since they bind the same receptor, the LHCGR (1), 
which is mainly expressed in the gonads, and similarly activate the classical cyclic adenosine 
monophosphate (cAMP)/protein kinase A (PKA) steroidogenic pathway. In clinical practice 
human CG (hCG) is the hormone of choice when LH activity is needed, e.g. in the treatment 
of hypogonadotropic hypogonadism (HH) or in assisted reproduction technologies (ART), 
because it is easily purified in high concentration from urine of pregnant women. By an 
historical perspective, human LH of pituitary origin was difficult to obtain and lacked of full 
biological activity since embedding a proteolytic site leading to internally cleaved hormones, 
thus displaying half of the activity of the intact molecule (2,3). Human recombinant LH 
became only recently available for clinical use in ART, but there is insufficient experience to 
draw conclusions about different, specific indications for LH and hCG in clinical practice. As 
a result, the idea that human LH and CG (hCG) may be used indifferently remains dogmatic. 
However, since evolution led to the appearance of several copies of the CGB gene in 
primates, the equivalence between the two gonadotropins with “LH activity”, interacting with 
the single receptor, needs a critical reassessment. Physiological considerations suggest that 
LH is unique and fundamental for gametogenesis regulation, while the evolutionary onset of 
CG genes might be linked to the requirement of different signals specifically supporting 
pregnancy in primates. Modern technologies and recent in vitro data allow the evaluation of 
multiple signaling pathways, activated by a number of LHCGR interactors (4,5). A recent 
report suggests that a complete picture of LH and hCG action might be missing when 
exclusively investigating the classical cAMP/PKA steroidogenic pathway (6). In vivo and in 
vitro studies using rodents or rodent-derived cells provided informative results in 
understanding the physiology of gonadotropins (7,8). However, since rodents do not have 
CGB genes, they do not produce CG and the murine LH receptor is not identical to the human 
one (88% of identity between Rattus norvegicus Lhr and LHCGR). Some recent evidence 
suggests that the human LHCGR possesses a specific region capable of distinguishing 
between LH and hCG (9). These studies raise the question whether hCG and LH really are 
equivalent and fully interchangeable in humans. In addition, since rodents are still being used 
to calibrate gonadotropin preparations used in medical practice (10) and the physiology of 
LH action was mainly obtained from murine models, another question is whether the primate-
specific nature of the dual ligand system provided by LH and CG has been completely 
characterized. Some clinical (11) and in vitro (6,12) comparisons of commercial LH and hCG 
preparations have been performed in the last fifteen years, revealing the existence of several 
peculiarities but leaving many unanswered questions.  
In this article we review current evidence about similar and different functions of LH and 
hCG. 
Two ligands for one receptor. Why? 
Ligands and receptors evolved along with their molecular targets, resulting in exclusive, 
hormone-specific regulation of pathways and physiological functions (13). In primates, the 
existence of LH and hCG as ligands for the same receptor suggests that a separation of 
hormone-specific roles occurred, resulting in different, hormone-specific physiological 
functions. These distinct roles may exist to fulfill different requirements for the regulation of 
fetal development (in females) and gametogenesis (in both sexes). These reproductive 
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functions are accompanied by the prevalent – or even exclusive – time- and sex-dependent 
presence of only one of the two hormones, pointing towards specific physiological targets 
reasonably regulated by different endocrine signals (6). LH- and hCG-specific actions exerted 
at the molecular level are underpinned by different molecular structures associated with each 
hormone (14), which arise from a different set of related genes (14), along with source cell-
dependent post-translational modifications (15). Although heretofore considered "equivalent" 
both hormones divergently evolved in primates and are characterized by differences at the 
genetic, molecular and physiological level. 
Although the specificity of LH and hCG signals is not completely elucidated, it is 
supported by the different nature of their target cells. In women of fertile age, LH exerts its 
best-known functions in the ovary, where it mediates proliferative signals in the granulosa 
cells co-expressing the follicle-stimulating hormone (FSH) receptor (FSHR) and LHCGR, 
and stimulates androgen synthesis, mainly androstenedione, in theca cells exclusively 
expressing LHCGR. Moreover, LH induces luteinization of granulosa cells, progesterone 
synthesis and corpus luteum maintenance during the luteal phase of the menstrual cycle. In 
males, Leydig cells in the testis are targeted by LH, which induces testosterone production, as 
the major synthesized androgen. LH is therefore essential for reproduction in both sexes. On 
the other hand, hCG physiological action is only exerted in females as a massive 
progesterone stimulator in the corpus luteum and mediating placental growth during 
pregnancy, while it is not produced in males. These considerations suggest a sex-specific role 
of each hormone in humans and other primates. Such roles are quite different (gametogenesis 
vs. pregnancy) and most likely not fully interchangeable. In fact, clinical experience shows 
that steroidogenesis and gametogenesis can be supported by hCG administration in both 
sexes, but is human (primate) pregnancy sustainable by LH in the absence of hCG? In 
assisted reproduction, hCG is administered to provide LH-like activity based on the 
androgen-stimulating potential of the molecule. However, is the action of both molecules on 
gamete maturation identical? Compelling results were provided by a comparison between LH 
and hCG administered to mouse oocytes cultures at the germinal vesicle stage in vitro. A 
greater maturation rate following hCG treatment was revealed, while LH positively impacted 
early embryonic development (16). These data, albeit obtained using mouse tissues, suggest 
that different signals are mediated by each ligand, resulting in different effects on the 
physiological target. This is but one example of a number of recent in vitro and clinical 
studies providing a novel, unexpected view of LH- and hCG- specific roles. In the following 
paragraphs we will define such different roles starting from evolutionary considerations. 
II.  Phylogenies and evolution of LH and hCG 
Molecular structures of gonadotropins and their receptors are overall conserved during 
evolution and share similarities with several other ligands and receptors across the phylogenic 
tree. This hints at a common ancestral origin of these molecules and the promiscuity of 
molecular mechanisms involved in endocrine regulation. Gonadotropins are glycoprotein 
hormones belonging to the superfamily of cystine knot growth factors (CKGF). Members of 
the CKGF group share an arrangement of six disulfide-linked cysteine residues that achieve a 
structurally related "knot" conformation, in spite of a relatively low sequence homology (17). 
Glycoprotein hormones possess a common α and a specific β subunit, assembled to form a 
non-covalently linked heterodimer (18) acting on specific leucine-rich repeat (LRRs), 
rhodopsin-like G protein-coupled receptors (GPCR). It was estimated that the evolutionary 
origin of glycoprotein hormones and their receptors occurred at the origin of the metazoans: 
hence, they organize the regulation of a wide range of endocrine systems as well as 
reproductive and metabolic functions that differentiated during evolution (19). Such 
evolutionary issues were inferred by evaluating genetic structure of gonadotropin and their 
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receptors encoding genes. A number of glycoprotein hormones, i.e. gonadotropins, and 
receptor variants developed as an endocrine adaptation to specific environmental conditions 
and physiological changes required to improve reproductive success (fitness) tested by 
natural selection (20). As an example, fertile window length, menopausal age and high 
pregnancy success may be the result of species-specific, or even individual-specific, 
optimizations of reproduction implemented to best balance fitness and selective pressure. In 
primates, the appearance of choriogonadotropic hormones acting as additional ligands for one 
receptor suggests that different levels of regulation are required to manage gametogenesis and 
pregnancy. 
Glycoprotein hormones across the phylogenic tree 
 Glycoprotein hormones and their receptors revealed common structural folds 
suggesting a common evolutionary origin of ligand-receptor pairs, likely resulting in similar 
and even promiscuous binding and signaling mechanisms. Binding specificity would be 
driven by the protein sequence spanning between the 10th-12th cysteine residues of the 
hormone, consisting of similar sequences and falling within LRR domains of their receptors 
(21). In insects, the only molecule related to vertebrate glycoprotein hormones is the 
bursicone hormone, an approximately 40 kDa protein displaying cystine knot heterodimeric 
structure and pro-apoptotic activity at the epidermal level (22). The analysis of the bursicone 
hormone-encoding DNA sequence revealed high identity with glycoprotein hormone-like 
peptides found in silkworm, sea urchin, jellyfish and corals, suggesting their evolutionary 
proximity (19). Similar homologies were found by comparing the DNA sequences encoding 
the hormone receptors, demonstrating that the ligand-receptor system underwent co-
evolution. Interestingly, co-expression of the LHCGR gene is coupled to the canonical cAMP 
pathways in transgenic Drosophila melanogaster like in humans, further supporting 
conservation of the intracellular machinery necessary for GPCR signaling in invertebrates 
(23). An evolutionary step towards vertebrates may be provided by a glycoprotein hormone 
of adenohypophysial origin found in hagfish. This hormone consists of bound α and β 
subunits and the presence of their mRNAs matches the developmental stages of the gonad 
(24), likely providing the earliest pituitary-gonadal system in vertebrates. In basal vertebrates, 
such as the hagfish, unique glycoprotein hormones regulate all the cognate gonadotropin 
functions found in mammals, by acting on distinct receptors (fshr and lhr) mediating 
gametogenesis (25). This ancestral form of glycoprotein hormone, homologues of which are 
conserved in vertebrates and some invertebrates, is known as thyrostimulin and is capable of 
increasing intracellular cAMP in cell systems expressing lamprey glycoprotein hormone 
receptor (26). The evolutionary history of more physiologically specialized gonadotropins 
started about 927 million years ago, when the ancestral gene encoding the thyrostimulin β 
subunit repeatedly duplicated resulting in an LHβ encoding gene from which the thyroid-
stimulating (TSHβ) and the follicle stimulating hormone β subunits (FSHβ) encoding genes 
subsequently originated (27). Further molecular specializations occurred in primates and 
equids, where CGβ and CGβ-like LHβ molecules respectively, developed as gonadotropins of 
pregnancy. 
Co-evolution of glycoprotein ligands and their receptors testifies to the specificity of the 
glycoprotein-mediated signals demonstrated in cartilaginous fishes, providing an ancient 
representation of the current diversity of reptilian, avian, and mammalian endocrine systems 
(28). However, endocrine signal promiscuity is retained in some organisms such as zebrafish, 
where fsh binds both fshr and lhr, while only lh is specific for its own receptor (29). As a 
consequence of this incomplete functional differentiation, the endocrine control of 
spermatogenesis in zebrafish relies on fshr expression in both Leydig and Sertoli cells (30). 
Interestingly, fish gonadotropin receptors may be activated by mammal cognate ligands and 
vice versa, suggesting a limited number of specific binding residues conserved during 
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evolution, even in the case of hCG binding to fish lhr (31). The sharing of inter-specific 
binding capability between gonadotropins and their receptors is maintained across fish and 
mammals as a legacy of common ancestral evolution. Moving from invertebrates to primates, 
on the other hand, increasing complexity and specificity of glycoprotein hormones and 
receptors is the requisite of the refined function of the pituitary-gonadal axis: the result is an 
increasing endocrine specialization with species evolution. 
LHB gene duplication: the appearance of choriogonadotropin 
 LHβ and CGβ subunits are encoded by a cluster of tandem genes, located in humans 
on chromosome 19q13.32, which embeds a total of eight genes and pseudogenes (32). There 
are six transcriptionally active CGB genes (33) and related promoters (34). The LHB/CGB 
gene cluster reaches the highest complexity in Homo sapiens, while other primates feature a 
simpler organization characterized by fewer CGB genes. Since most of the 5% difference 
between humans and chimpanzees is due to genomic insertions and deletions (35), CGB 
genes putatively evolved by repeated duplications of an ancestral LHB gene common to all 
species of the primate lineage, to meet specific physiological requirements (36,37). High 
crossover activity putatively occurred in the human LHB/CGB cluster and resulted in 
sequence inversions generating palindromic genes (38). One of the most accredited theories 
explains the rise of CGB genes along with the increasing glycosylation rate of CGβ 
molecules as evolutionary adaptations to elevated energy demands for fetal development: the 
resulting highly specialized regulation of angiogenetic signals and myometrial invasion is 
necessary to support hemochorial placentation in humans and higher primates (15). Thus, six 
CGB genes are found in humans, four to five in great apes and three to one among Macaca, 
Callicebus and Aotus (39). The highly conserved CGB1 and CGB2 gene sequences in humans 
and great apes suggest they may have relevance for implantation and placental development 
in higher primates (40). Other CGB genes, namely CGB, CGB5, CGB7 and CGB8, are 
recognized to be a source of hCG products during human pregnancy (41). Accordingly, 
simpler primates (e.g. strepsirrhine) and other mammals have only one LHB gene and feature 
epitheliochorial placentation characterized by the presence of both the uterine epithelium and 
the maternal vascular endothelium during pregnancy. The theory explaining the rise of CGB 
genes has recently been extended (20). Sex-specific functions, i.e. placentation, 
folliculogenesis and ovulation in females and spermatogenesis in males, would be driven by 
the expression of sex-specific genes belonging to the same genomic cluster. In this context, 
the LHB gene is relegated to maintenance of physiological functions common to both males 
and females, since they may need similar regulation at the intracellular level, while CGB 
genes permitted independent evolution of signals specifically required for placentation in 
females, as an example of sexual dimorphism. This strategy might have arisen to solve an 
intralocus sexual conflict, which occurs when traits encoded by the same locus lead to 
conflicting fitness outcomes between the two sexes (42). However, the evolution of 
placentation in primates might be linked to the gene encoding the glycoprotein hormone α 
subunit (common glycoprotein alpha, CGA) (43). This gene has two splice variants, one of 
which is only found in anthropoid primates with the exonization of an Alu sequence. The 
additional encoding sequence results in a N-terminal extension improving protein stability. 
Similarly, CGB genes are characterized by an additional DNA sequence compared to LHB. 
Although a certain grade of similarity is shared among genes encoding glycoprotein 
hormones β subunits, CGBs display a peculiar extension of about 90 nucleotides compatible 
with 30 amino acids at the C-terminal region (44). This carboxyl-terminal extension (CTP) 
could have originated from the loss of the stop codon occurring together with the duplication 
of an ancestral LHB gene, resulting in inclusion of the 3'-untranslated region within the 
protein coding sequence, which is absent in all known mammalian LHB genes, except equids 
(Table 1). The human CTP domain contains four potential O-linked glycosylation sites, is 
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6
enriched in serine, threonine and proline residues (45) and may be targeted by specific 
antibodies due to the immunological potential of the glycosylated sites (46). 
 [TABLE 1] 
Classical views of LH and hCG physiology 
 Although the diversification of endocrine axes and the appearance of CG molecules 
suggest that different LH receptor-dependent intracellular functions are required to regulate 
gametogenesis and pregnancy, experimental and clinical observations in women and female 
primates failed to clearly distinguish the actions of these molecules during gametogenesis 
(47) and luteal regression (48). Thus, it is a widely accepted opinion that these two molecules 
are equivalent. However, the evaluation of gonadotropin-specific functions in human 
physiology points to distinct, cell-specific roles for each molecule. In ovarian granulosa cells, 
proliferative signals directly delivered by LH are not necessarily exerted through the 
synthesis of androgens, which instead are the main product of LH action in theca cells. On 
the other hand, hCG naturally only replaces LH in the luteal phase and beyond, during 
pregnancy, when steroid production is mainly limited to progesterone. 
In humans, gametogenesis progresses thanks to an orchestrated regulation by FSH, LH, 
growth factors and steroid hormones. In women, the ovarian follicle is the functional unit 
deputed to oocyte maturation and growth, characterized by a dynamic structure of somatic 
cells surrounding the gamete (49). Folliculogenesis starts about 20 weeks after conception, 
when the follicular population comprises 4-7 million oocytes at the resting primordial stage. 
Pools of these follicles progressively mature by undergoing morphological and molecular 
changes, and passing through the primary and secondary, gonadotropin-independent stages. 
Subsequently, from the pubertal onset, monthly recruitment is guided by the expression of 
FSH receptor (FSHR) and LHCGR at relatively low but progressively increasing levels (50) 
conferring follicular sensitivity to FSH. This is the proliferative signal for granulosa cells, 
which start to replicate and synthesize steroid hormones, inducing antrum formation and 
supporting oocyte maturation. At the early follicular phase, relatively low LH levels are 
produced, and it is commonly accepted that these are enough to mediate androstenedione 
synthesis by LHCGR-expressing theca cells (51). On the other hand, relatively high levels of 
FSHR are exposed at the surface of granulosa cells, which express low levels of LHCGR (52) 
as well, suggesting a physiological role of the putative interaction described to occur between 
these two receptors (53) in modulating gonadotropin signals (54). If the coexistence of FSHR 
and LHCGR has a biological significance, it is exquisitely granulosa cell-specific, since 
FSHR is absent in theca cells. Most importantly, these data suggest that LH- and FSH-
dependent synergetic action in granulosa cells, not provided by each gonadotropin per se, is 
required to properly guide follicular growth. At this stage, the best-known role of theca cells 
still is to supply androstenedione, as the substrate for estrogen production in granulosa cells, 
supporting follicular growth and oocyte maturation/metabolism. As pituitary FSH release and 
follicular FSHR expression decline, LH levels increase along with the progression towards 
the large antral stage, when follicular growth is gonadotropin and estrogen-dependent. 
However, both FSH and LH production still co-exist at this stage, with both proliferative and 
apoptotic signals occurring in the dominant and atretic follicles, respectively. In the late 
follicular phase, LHCGRs fully replace FSHRs in granulosa cells of the dominant follicle, to 
induce both ovulation and the changes in metabolic state necessary to luteinization, i.e. 
massive, exclusively LH-driven progesterone production. Therefore, while both FSHR- and 
LHCGR-mediated life and death signals are simultaneously present in granulosa cells, only 
LH-dependent signals of increasing potency are delivered to theca cells over the entire 
follicular phase up to ovulation. Thereafter, the second half of the menstrual cycle depends on 
progestational signals transitorily supported by LH in the corpus luteum. Only in the case of 
pregnancy is corpus luteum function maintained by trophoblast hCG, because LH levels 
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7
decrease as a consequence of the negative feedback exerted at the hypothalamo-pituitary 
level by high progesterone concentrations. Therefore, physiologically, the steroidogenic LH 
activity in the ovary is not naturally taken over by hCG prior to this stage. The progression of 
pregnancy features steadily increasing progesterone levels, which, during the first 7-10 weeks 
of gestation are due to the hCG action on the corpus luteum (55). It is well known that hCG 
stimulates the maternal androgen production required for fetal development and pregnancy 
progression (56). Moreover, it seems that both placental and adrenal androstenedione and 
testosterone play a role in cervical and myometrium remodeling and parturition (56), while 
excessively high androgen levels might compromise maternal health (57). Apart from these 
functions, little is known about the direct action of hCG on androgen synthesis, whereas the 
role of the gonadotropin is classically associated to progesterone synthesis during pregnancy. 
hCG is secreted in high amounts, especially in the first trimester of pregnancy and acts as 
an essential, potent steroidogenic factor. Other functions have been, however, hypothesized 
for hCG, e.g. immunosuppressive and angiogenic functions, especially during the early 
weeks of pregnancy (58), as well as the capability of enhancing steroid-mediated signals by 
activating cAMP- and extracellular-regulated kinase 1/2 (ERK1/2)-mediated production of 
the progesterone receptor in endometrial cells (59). The exposure to maternal hCG is crucial 
for fetal sex steroid production and activation of the hypothalamus-pituitary-gonadal (HPG) 
axis, which impacts fertility potential in adulthood (60). After birth, maternal estrogens 
decline in the newborn, leading to the rise of FSH and LH characterizing the neonatal period 
dubbed mini-puberty. This results in a surge of pituitary gonadotropins of a magnitude only 
comparable to the levels obtained much later, at puberty (61). 
FSH and LH signaling are fundamental for male gametogenesis as well, since these 
hormones act on Sertoli and Leydig cells, respectively, providing mechanical and endocrine 
support to sperm production. The hormonal control of spermatogenesis and, especially, its 
dependence on FSH or LH, are extremely species-specific among mammals (25), although 
testosterone is in general an essential requirement for the progression of gamete maturation. 
Testosterone is produced by Leydig cells upon LH stimulation and sustains Sertoli cell 
function and spermatogenesis progression, albeit being partially converted to 17-β-estradiol 
by the aromatase enzyme, promoting anti-apoptotic signals, likely together with 
gonadotropins (62,63). Given the steroidogenic role of Leydig cells, which indeed express 
LHCGR, but not FSHR, it is understandable that hCG found clinical utility in replacing LH 
functions. Since the use of LH for treatment of male HH is still limited, even in the era of 
recombinant gonadotropins, no substantial data are available to differentiate its action from 
that of hCG in males. 
Studies focused on the metabolic fate of gonadotropins indicated that only about the 22% 
of hCG is excreted in the urine, while the retained hormone is resorbed and degraded mainly 
in the kidney and, in a lesser extent, liver, and ovary (64). In the kidney, these molecules are 
metabolized to β core fragments deprived of galactose, sialic acid and CTP fragment, 
suggesting that these modifications are required for urinary excretion. In fact, sugar moieties 
play a key role in establishing the circulatory half-life of LH and hCG. Routes and rates of 
LH/CG distribution and elimination were compared in rats and piglets, revealing that high 
quantity of radio-labelled porcine LH (pLH) is accumulated in the kidneys within 10 min 
from injection, while eCG plasma concentration is 80% after 1 h and the hormone is not 
accumulated in any organ (65). Taking together, these data indicate that LH is eliminated 
from serum by renal trapping, resulting in rapid removal compared to CG. Other, minor 
routes for gonadotropin elimination may be found in the liver, through binding of sulfated 
oligosaccharides to a specific receptor (S4GGnM) expressed in the Kupffer cells (66). 
Gonadotropins are subsequently processed in the kidney to be excreted with urine as residual, 
highly similar LHβ and hCGβ core structures, identical to the original pituitary and 
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trophoblast core molecules (67). This is due to the relatively high stability of the 
gonadotropin structure, which is nearly identical among LH and CG molecules of humans 
and other primates (68), suggesting that urinary excretion of highly similar gonadotropin core 
metabolites might be evolutionarily conserved. 
In summary, LH and hCG are involved in the regulation of multiple physiological 
functions, but their specificity is underrated due to their action through the same receptor and 
clinical experience derived from the use of readily available hCG only in the treatment of HH 
and in controlled ovarian stimulation (COS) for ART. In the latter case, gametogenesis may 
be clinically supported by administration of exogenous FSH and hCG, thereby at least 
partially replacing LH action. However, clinical data did not provide representative models 
for understanding LH- and hCG-specific functions in vivo so far. For instance, stimulation of 
multiple oocyte production in the clinical setting of COS is far from replicating the natural 
oocyte selection, since it results in multifollicular development in a mono-ovulatory species. 
This effect is due to the pharmacological gonadotropin dosages, which do not necessarily 
elicit physiological patterns of estrogen production and oocyte selection.  
Evolutionary convergence: trophoblast LH and pituitary CGs 
 The endocrine adaptation to pregnancy results in different, interesting evolutionary 
strategies exhibited across the phylogenic tree of mammals. The analysis of the lhb genomic 
locus of several species suggests that the CTP fragment might be produced by a number of 
organisms by frameshift of the gene transcription (69). Data suggest that the concept relating 
the CTP fragment with placentation of primates may be extended to all mammals (70), which 
share the potential to produce glycoproteins bearing the CTP peptide which likely possesses 
the key characteristics of hCG. A proof of concept may be provided by the bovine, which 
produces a pregnancy LHβ variant featuring a CTP fragment. This molecule is produced by 
decryption of the 3’ region of the lhb gene, resulting in a glycoprotein hormone which is 
however poorly O-glycosylated and displays lower half-life compared to hCG, not supporting 
the evolution of CG molecules in bovines (71). 
 A placental gonadotropin was described in equids long ago (72,73). This hormone is 
known as equine choriogonadotropin (eCG), suggesting a similitude to CG molecules of 
primates. However, both β subunits of equid pituitary LH (eLH) and trophoblast eCG are 
products of the same lhb gene. They differ in source of production and N-linked 
glycosylation, which is higher for eCG than eLH, while O-linked glycosylation is crucial for 
both hormones to maintain binding activity (74). Moreover, both eCG and eLH demonstrated 
binding capability for fshr (75), which results even higher for eLH than eCG (76), suggesting 
a role in mediating FSH-like signals. In fact, eCG capability of promiscuous fshr activation 
was described in most mammals (77,78), while, however, could be negligible in horses (79). 
These gonadotropins consist of glycosylation variants providing a case of evolutionary 
convergence between equids and primates: different strategies are adopted to support the 
same physiological process. 
 Interesting data were provided by studies of primates, which seem to be an 
evolutionary counterpart to bovines and equids when considering LH and CG. Two decades 
ago, LH bioactivity in the New World marmoset monkey Challithrix jacchus was 
demonstrated to be produced by a pituitary choriogonadotropin (mCG) sharing about 80% 
identity with hCG (80). mCG displays multiple activities regulating development, 
gametogenesis and pregnancy, likely due to a glycosylation pattern similar to human LH and 
a CTP structure similar to hCG. On the other hand, the marmoset monkey LHCGR lacks the 
amino acid sequence encoded by exon 10 of the gene, which corresponds to an extracellular 
portion of the receptor (81). Although the molecular structures of gonadotropin and their 
receptors will be detailed in the next chapter, the presence of a CG molecule and the lack of 
exon 10-encoded sequence in C. jacchus LHCGR (also known as LHCGR type II) in the 
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entire New World monkey lineage, provide interesting information about the LH/CG-
receptor functioning, which reaches its maximum complexity in primates (82). Indeed, a 
previous study suggested that the CTP fragment is essential to induce LHCGR type II 
activation (83). In light of these studies, an interesting finding described an 18-year old 
patient with Leydig cell hypoplasia characterized by the absence of exon 10-encoded portion 
of the LHCGR, who was unresponsive to endogenous LH (84). As a consequence, this boy 
had relatively high serum LH and very low testosterone levels, delayed pubertal development 
and small testicles, indicating deficit of the LH signal. Surprisingly, testosterone biosynthesis 
and spermatogenesis were recovered by hCG treatment. hCG also induced cAMP production 
during functional analysis in vitro assessed in exon 10-deficient LHCGR-transfected cells, 
which LH failed to stimulate despite binding to receptor (85). This clinical case confirmed 
the importance of the amino acid region encoded by the exon 10 of LHCGR to discriminate 
between the two natural ligands, supporting the concept of co-evolution of the ligand-
receptor structure as a strategy to regulate gametogenesis and placentation in primates (Figure 
1). 
[FIGURE 1] 
While it might be intuitive to find the structure-function relationship of placental 
gonadotropins, the role of hCG and hCGβ molecules found in the human pituitary (86) is still 
unknown. They were detected in the serum of both men (87) and women (88), and would be 
released in a pulsatile fashion. It was postulated that pituitary hCG molecules might play a 
role in the regulation of the menstrual cycle (89) and ovarian pathogenesis (90), but further 
evidence is needed to support this issue. 
III. Different sources, molecular structures and biochemical properties 
 The genetic differences of LH and hCG reflect gonadotropin-specific molecular 
structures, post-translational modifications and biochemical properties at least partially 
established in the secretory pathway, involving endoplasmic reticulum and Golgi apparatus of 
the source cell (91). The secretion of LH by gonadotrope cells of the anterior pituitary is 
controlled by the gonadotropin-releasing hormone (GnRH) (92), a peptide produced by the 
hypothalamus, under kisspeptin regulation (93), in a pulsatile fashion and released into the 
portal bloodstream. GnRH binds its seven-transmembrane receptor (GnRHR) expressed in 
gonadotrope cells, mainly activating phospholipase C (PLC), ERK1/2-, β-catenin, calmodulin 
and PKA-dependent signaling (94,95). The preferential LH or FSH synthesis depends on the 
frequency of GnRH pulses: low frequencies are linked to FSH production, while higher 
frequencies are synchronized with waves of LH synthesis (96). In women, the preovulatory 
stage of the menstrual cycle is characterized by a GnRH surge corresponding to the LH 
increase inducing ovulation. Given the dependence of gonadotropin production on kisspeptin 
and GnRH, a new model of ovarian physiology was proposed, where follicle maturation and 
selection, ovulation and luteal phase occur under the strict control of the neuroendocrine 
system (97). In fact, the relationship between gonadal and pituitary functions was shown by 
experiments in Lhr knockout (LuRKO) and ovariectomized mice (98). In both these models, 
high expression of gonadotropin subunit genes occurred, reflecting morphological changes in 
gonadotrope cells, which display secretory granules larger than in wild-type mice. In contrast, 
in GnRH-deficient mice expressing low gonadotropin mRNA and protein levels, gonadotrope 
cells were smaller and featured fewer secretory granules. Interestingly, a variety of LHβ 
molecules may be produced in humans, even if not completely functionally characterized yet. 
They differ in glycosylation patterns, resulting in specific molecular weights (99). 
 The secretion of hCG by trophoblast cells occurs in a non-pulsatile, increasing 
manner, reaching the peak around the first trimester of pregnancy, and is not coupled to 
GnRH production. A wide variety of hCG isoforms and glycosylation variants are produced 
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during this period, promoting trophoblast invasion of maternal decidua. Most interestingly, 
and in contrast to LH, hCG production is not subjected to immediate down-regulation by 
steroid hormones. It could be speculated that steroidogenic hCG-mediated signals are 
constantly delivered during pregnancy as a requirement to maintain proper progesterone 
production, while the different nature of LH is aimed at more transitory events, such as 
luteinization, which need not be prolonged. A suggestive explanation of the molecular 
mechanism underlying constant hCG activity may be provided by the discovery of an about 
50 kDa-truncated form of LHCGR, specifically expressed by placenta and choriocarcinoma 
cells, the presence of which is concomitant to the absence of hCG down-regulation (100). 
The presence of this truncated receptor would be opposed to the appraisal of full-length 
(about 90 kDa) LHCGR at the term-placenta, which suggests the existence of a feedback 
mechanism regulating hCG action via receptor downregulation. While these findings should 
be independently confirmed, it is known that hCG production is constant but undergoes 
qualitative dynamic changes over pregnancy. It has been suggested that the pattern and 
abundance of hCG molecules is individual-specific, thus, choriogonadotropin acts as a 
dynamic, autocrine factor which changes qualitatively throughout the first trimester of 
pregnancy (101). hCG isoforms consist of different polypeptide products selectively 
transcribed by CGB genes (102), while the oligosaccharide structures differentially linked to 
the hCG backbone determine the glycosylation variants and would depend on the enzymatic 
milieu of trophoblast cells, which differs from that of pituitary gonadotrope cells (103). 
 The effects of oligosaccharide structures, especially O-linked, are apparent in the 
serum half-life differences between the two hormones, which is of 90 minutes for LH and 34 
hours for hCG (104). In particular, O-linked glycosylation is abundant in the CTP fragment 
of hCG and could be important to determine hormone-specific physiological roles, providing 
a strategy for developing chimeric gonadotropins with slow metabolic clearance (105). In 
gonadotrope cells, gonadotropin glycosylation is modulated by a number of hypothalamic 
and gonadal endocrine factors, such as estrogens and androgens (106). These steroids may 
also impact on sialylation and sulfation of the oligosaccharide, further modulating half-life 
and biopotency, thus extending the qualitative range of signals delivered to the gonads. On 
the other hand, sulfation of oligosaccharides is critical for hormone half-life and bioactivity. 
Indeed, this post-translational modification is evolutionarily preserved among glycoprotein α 
subunits, from teleost fishes to mammals (107). Finally, it is reasonable, albeit speculative, 
that the pulsatile release of a short half-lived LH would provide a fine-tuned stimulus 
optimized to regulate life signals mediating follicle growth, while hCG molecules trigger the 
relatively potent stimulus for sustained and prolonged progesterone synthesis and 
angiogenesis. In summary, two different gonadotropins, LH and hCG, should be recognized 
at the receptor level in order to reach a finer level of regulation, not allowed by a unique 
ligand, mediating specific intracellular signals required to optimize reproduction and 
development. 
Production of alpha and beta subunits 
 Production of glycoprotein α subunit is a rate-limiting step for gonadotropin 
heterodimer formation. The α subunit, encoded by the 9.4 Kb CGA gene (108), transcripts of 
which are found in pituitary and placenta, serves for glycoprotein hormone heterodimer 
assembly occurring in the endoplasmic reticulum of source cell (109). Both hCGα and β 
subunits are characterized by three loops defined by a cysteine knot and experimental 
evidence proved the importance of the second loop of the α subunit in dimer formation. 
These results were obtained using chimeric molecules, where the second loops of hCGα and 
β subunits were swapped, resulting in β-β homodimers capable of receptor binding and 
activation of signal transduction, albeit at lower levels than wild-type hCG, and inactive α-α 
homodimers (110). The knowledge of how the formation of glycoprotein hormone 
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heterodimers occurs was improved by several attempts to develop the crystal structure of 
hCG over a five-year period from 1989 to 1994 (111–113). These models revealed interesting 
features of the molecule, mostly the seat belt-like structure composed of a segment of the β 
subunit wrapping around the α subunit loop αL2 linked by a disulfide bridge between two 
cysteine residues at positions 26 and 110 of the polypeptide chain. However, a complete view 
of the tridimensional dimer structure was strongly hampered by the oligosaccharide structures 
bound to hCG. Again, experiments using mutant α subunits lacking the disulfide bonds 
between cysteine residues at positions 7-31 and 59-87 provided a further step in 
understanding the procedure of gonadotropin heterodimer formation (114). Disruption of 
these structures did not significantly affect hCG or FSH heterodimer formation, while it 
negatively impacted LH heterodimerization in transfected Chinese hamster ovary (CHO) 
cells and in the rat pituitary tumor cell line, GH3. On the other hand, N-linked glycans at 
position 13 and 30 are required for the efficient hCGβ folding and formation of disulfide 
bonds between the residues at position 23-72, 93-100, and 26-110 (115). These data suggest 
that regions recognized by the α subunit for assembly are different in LHβ and hCGβ. 
New insights on formation of LH and hCG dimers were provided by recent advancements 
allowing the evaluation of molecular interactions by means of a bioinformatic approach. This 
in silico analysis revealed that dimer assembly might follow different β subunit-specific 
modes, depending on the presence or absence of the hydrophobic tail of LHβ and hCGβ, 
respectively (116). The LHβ subunit is not completely folded when docking with the α 
subunit occurs. In this case, the α subunit acts as a scaffold using the cystine knot to enhance 
β-subunit cystine knot formation. The heterodimer is then stabilized by the interaction 
between loop 2 of the α subunit and the β subunit hydrophobic tail, which form the seat belt-
like structure. This LH-specific mode of dimer formation was named “wraparound” and 
differs from the assembly of the hCGα-β dimer, which was named “threading”, in order to 
explain the mechanism by which the α subunit passes between a β subunit folded before the 
docking. An alternative mechanism, similar to the “wraparound” model, also was proposed 
for hCGα-β dimer formation (117,118). However, these data suggest that different 
heterodimer assembly may have arisen as a strategy to control the production of the two 
hormones. In fact, while hCG assembly is efficiently performed, in vitro experiments using 
chimeric gonadotropins revealed that LH assembly and secretion is less vigorous (119). 
Faster rate of hCG than LH secretion presumably reflects their massively constitutive and 
GnRH-regulated secretory pathways, respectively. The CTP fragment of hCG plays a role in 
determining heterodimer formation, since CTP-truncated forms of the chorionic hormone 
resulted in a 60% decreased efficiency of dimerization. Interestingly, removal of the LHβ C-
terminal octapeptide increased the rate of hormone secretion by transfected CHO cells, 
confirming the relevance of the carboxy-terminal region of LH and hCG for their physiology. 
Previous attempts to produce recombinant LHβ and hCGβ in transfected GH3 cells in 
vitro revealed the role of the N-terminal region in the disulfide-linked aggregation of LHβ 
subunits, whereas hCGβ was exclusively secreted as a monomeric molecule. Further 
investigation using mutant gonadotropins demonstrated that N-glycosylation on the 
asparagine at position 13, which LHβ lacks, prevents hCGβ aggregation in culture medium 
(120). These data indicate that glycosylation in the N-terminal region of the two 
gonadotropins plays a role in the maintenance of the correct folding and secretion in the 
absence of the α subunit (Figure 2). Most importantly, this finding may explain the 
measurable presence of free hCGβ subunits during pregnancy, when high activity of CGB 
genes leads to massive protein production, while free LHβ subunits are relatively rare (121). 
[FIGURE 2] 
The LHβ subunit 
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 LHB gene transcription is stimulated upon GnRH binding to its receptor, activating 
Gq/11 proteins and stimulating phospholipase C to mediate inositol 1,4,5-triphosphate and 
diacylglycerol pathways. These intracellular messengers lead to protein kinase C (PKC) 
activation, intracellular calcium increase and β-catenin signaling regulating the expression of 
the LHB gene. The latter is under the control of GATA and chicken ovalbumin upstream 
promoter-transcription factors (COUP-TFI and COUP-TFII) (122,123), whereas the secretion 
of LH is regulated by the increase in intracellular calcium (124–126). The LHβ monomer was 
described several decades ago (127). It is an about 22 kDa glycoprotein of 121 amino acids 
subjected to post-translational modifications, which provide more than fifteen variants of the 
hormone, with molecular weights spanning from 11 to 24 and featuring specific bioactivity 
(99). The core fragment is structurally close to that of hCGβ except for the absence of the 
CTP fragment. Noteworthy, nomenclature of the amino acid position within LHβ and hCGβ 
subunits originated from these first sequence determinations (127–129), which excluded the 
20-amino acid long signal peptide. A new nomenclature including the length of signal peptide 
was proposed later (130) and is used to indicate amino acid positions in this article. 
Glycosylation, sulfonation and sialylation are the main LH modifications, which occur at 
different rates during the ovarian cycle (131) and with age (132). In particular, the LHβ 
subunit classically displays one N-glycosylation site at position 50 of the polypeptide chain, 
while two additional oligosaccharide structures are linked to the α subunit (133). LH 
heterogeneity consists of a prevalent glycoform carrying three oligosaccharide structures, 
except during mid-cycle when di-glycosylated LH is the main LH variant produced. 
Moreover, acidic forms of LH molecules increase with age and are mostly present in elderly 
women. Since the removal of these oligosaccharide structures by endoglycosidase treatment 
did not substantially change the LH steroidogenic activity, their functional significance may 
be related to other aspects of physiology (134). Oligosaccharides may be sulfonated or 
sialylated, resulting in different half-lives of the glycoprotein. Sulfated oligosaccharides 
consist of branches terminating in SO4-4GalNAc β 1,4, while sialylated oligosaccharides 
consist of a number of different structures featuring two or three branches and one to three 
sialic acid moieties (135). LH molecules with two or three sulfonated N-acetylgalactosamine 
(SO(3)-GalNAc) residues show shorter half-lives than less sulfonated LH, suggesting their 
rapid removal by hepatic Kupffer cells, whereas higher-sialylated gonadotropin isoforms 
have extended half-lives, likely due to the masking of the sulfonated oligosaccharides to 
S4GGnM binding and sequestration (136,137). However, rather than SO(3), sialic acid may 
be linked to LH GalNAc residues, likely resulting in extended half-life anyway (138). 
hCGβ isoforms and glycosylation variants 
In humans, a number of CGβ isoforms and variants are provided by transcription of CGB 
genes and different patterns of glycosylation, respectively. These types of hCG are known as 
“classical” hCG, hyper- and hypoglycosylated hCG, nicked isoforms and hCG lacking the 
CTP fragment, core fragments and free β subunits. These molecules represent a palette of 
multiple hCGβs differentially detectable as urinary products by specific immunoassays 
(139,140). 
Although in-depth functional characterizations of CGβ isoforms in vitro are missing, the 
expression pattern of CGB genes might be a determinant of the status of pregnancy or 
miscarriage. Although the regulation of CGB gene transcription is unclear, it is likely under 
the control of growth factors, cytokines, ligands of the nuclear peroxisome proliferator-
activated receptor γ (PPARγ) and steroid hormones, acting through the activation of cAMP-
mediated signals (141). In normal pregnancies, all CGB transcripts were found, especially 
CGB, CGB5, CGB7 and CGB8, which achieve a 1000- to 10000-fold higher expression levels 
than CGB1 and CGB2 genes (142). Ectopic pregnancy is characterized by perturbation of 
CGB expression patterns, in this case featuring a relatively high amount of CGB1 and CGB2 
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transcripts, while globally reduced CGB expression has been associated with miscarriage. 
Interestingly, relatively high amounts of CGB1 and CGB2 gene transcripts were found in the 
testis of healthy males, suggesting that they may play a still unknown role in male 
reproduction (142). 
Glycosylation is the post-translational modification providing more than a hundred hCGβ 
variants, depending on the combination of glycans specifically elaborated by the source cell, 
and attaching two potential N- and four potential O-glycosylation sites in hCGβ (143). 
Indeed, hCGβ isoforms possessing only one N-glycan are known and only three out of four 
O-glycosylation sites are typically decorated with carbohydrate (144,145). Moreover, up to 
fourteen glycoforms of the α subunit wre found, differing by sialylation, oxidation and N-
terminal truncation (146). Since hCG as well as LH are administered for infertility treatment 
as a mixture of different glycoforms resulting from the manufacturing processes and 
potentially featuring specific biochemical properties and bioactivities, the production of 
homogeneous hormone samples by chemical synthesis should be of great interest for clinical 
applications (147). Interestingly, during pregnancy of aneuploid fetuses, the profile of hCG 
glycoforms is different from that detectable in pregnancy of normal karyotyped fetuses (148). 
Although fully informative characterizations of these hCG glycoforms in vitro are missing, it 
was suggested that they are related to specific biological activities and functions, mainly 
angiogenic (149), in vivo (150). These conclusions were driven by experiments evaluating 
cell growth and migration in vitro mediated by hyperglycosylated hCG molecules (hCG-H) 
(151), predominantly produced during the early stages of pregnancy by extravillous 
cytotrophoblasts or by choriocarcinoma, and consistent with the positive regulation of early 
trophoblast invasion (152). hCG-H would have lower steroidogenic and higher proliferative 
potential than the “classical” form of hCG produced later (153). It should therefore be 
secreted during the very early days of pregnancy as an essential mediator of cell proliferation 
and maternal tissue invasion by fetal cells. In fact, insufficient hCG-H during the first days of 
pregnancy might be predictive of miscarriage (154), highlighting the fundamental role of this 
molecule for placentation and embryo development. Similar conclusions were drawn by 
analyzing the sera of women undergoing recurrent miscarriage, where anti-trophoblast 
antibodies inhibited the hCG-H release by the JEG-3 cell line in vitro (155). Interestingly, 
alternative, "hyperbranched" glycoforms linked to both α and β subunits are predominantly 
produced during aberrant pregnancy and by choriocarcinoma rather than in normal 
pregnancy, suggesting that the activity of Golgi processing enzymes takes place differently in 
malignancy (156). Hyperbranching may reflect the presence of free α and β subunits, which 
dimer formation is impaired by largely tri- and tetra-antennary glycans in contrast to those 
biantennary associated with classic hCG (157). The angiogenetic potential of 
hyperglycosylated hCGs is a crucial issue for pregnancy success, since a proper blood flow is 
required to avoid embryo hypoxia. This role may be exerted via activation of cAMP-
responsive elements located in the promoter region of vascular endothelial growth factor-
encoding genes (158). Interestingly, it has been proposed that angiogenic functions and 
trophoblast invasion of hCG-H could rely on growth factor-like activities putatively mediated 
through interaction between the hormone and the transforming growth factor β (TGFβ) 
receptor II (Tβ-RII), independently from the classical hCG signaling (159) (Table 2). A 
similar mechanism of action was suggested to explain tumorigenicity of free hCGβ subunits 
in BRCA1 gene-defective breast cancer (160). This is a suggestive hypothesis requiring 
further confirmation before being accepted, since an independent study revealed the opposite 
findings and suggested that experimental biases, such as TGFβ contaminations in the hCG 
preparations, may have affected the results (161). While the molecular mechanism underlying 
the proliferative potential of hCG-H is still unclear, it has been confirmed that these 
molecules are secreted by several tumor cells, even in the male (162), likely as a glycosylated 
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product occurring after metabolic reprogramming of tumor cells (163). These data suggest 
that hCG-H may be a tumor marker and promoter (164). 
[TABLE 2] 
LH and hCG binding to the human LHCGR: binding differences to non-human receptors  
Human gonadotropins display binding capability to non-human receptors. While 
indicative of overall structure preservation of these ligands and receptors during evolution, 
this is also relevant for clinical treatment of human infertility. LH and hCG dosage for 
clinical purpose is established by evaluating their biological activity against a standard using 
animal models not expressing the human receptor (165), suggesting some limits to their 
translation to the human and usage in clinical practice. The first evidence of LH and hCG 
receptor-binding was provided several decades ago, by in vitro studies using rat Leydig cells. 
These experiments found similar sets of binding sites and binding capacity for both hormones 
to the rat Lhr, evaluated by equilibrium association constants (Ka; hCG Ka = 7.6 x 10-10 M;
 
LH Ka = 2.5 x 10-10 M) and association rate constants (K1; hCG K1 = 3.4 × 108 M/min; LH 
K1 4.0 × 108 M/min) (12). However, higher binding affinity was suggested for hCG than LH, 
due to its longer persistence at the receptor level, and higher half-time of bound hormone 
(hCG = 25.0 h; LH = 9.2 h), thereby resulting in a reduced dissociation rate for hCG. These 
results suggest that the two hormones interact differently with the receptor, as a consequence 
of distinct amino acid sequences. Interestingly, it was observed that maximal hCG-mediated 
cAMP increase occurred at relatively low (<1%) Lhr occupancy in rat Leydig cells, 
adumbrating the existence of “spare” Lhr (166). This concept arose by evaluating the 
discrepancy between hCG binding and dose-response curves calculated for cAMP, which 
appeared to be left-shifted, and it has been recently used to explain the putative, steroidogenic 
activity exerted by LH during the antral phase of folliculogenesis (167,168). The putative 
existence of “spare” LHCGRs in the human ovary may be explained by the requirement for 
sustained androgen synthesis by theca cells, avoiding receptor down-regulation by LH. If so, 
then hCG must show a different action at the receptor level, during pregnancy, when the 
hormone is massively produced and constantly stimulates progesterone synthesis, somehow 
avoiding LHCGR downregulation. Although suggestive, these are largely conjectures, since 
the existence of “spare” LHCGRs was only suggested in vitro. Since hCG is not the natural 
ligand of rat Lhr, the parallelism between in vitro findings using rat Leydig cells and the 
physiology of the human ovary should be interpreted cautiously (169). On the other hand, 
LH-like signals may be driven by FSH through FSHR-LHCGR heterodimerization in 
granulosa cells (170), which should be favored by the about 1:100 ratio between LHCGR and 
FSHR amounts at the early antral stage (52). Moreover, ligand affinity to rat and human 
receptor might not be similar, as suggested by hCG and bovine LH, which both exhibit 
similar affinities for the rat Lhr, but different binding affinities for LHCGR (1000-10000 fold 
better for hCG than bovine LH) (171). These differences are due to an isoleucine residue 
falling within the C-terminal end of LRR2 of LHCGR, comparable to a serine residue in 
LRR2 of the rat Lhr, which would determine the LH-specific binding affinity (172). In vitro 
comparisons of human LH, hCG and some of their non-human, rat, equine, bovine, ovine, 
and porcine counterparts, in the mouse tumor Leydig MLTC1 cell line, revealed molecule-
specific control of adenylate cyclase activity, raising the question of whether hCG may be a 
reliable reference ligand in non-human LH receptor-expressing systems (173). These data 
suggest that Lhr and LHCGR might not be comparable and mediate receptor-specific 
responses. While the assumption of “spare” ovarian LHCGRs should at least be confirmed by 
binding experiments using radio-labelled LH and cells expressing the human LHCGR, it is 
clear that most of our knowledge of LH and hCG binding has been provided by experiments 
using cell models expressing non-human receptors, relying on the intra- and inter-species 
promiscuity between gonadotropins and their receptors but ignoring their differences. For 
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instance, conformational changes of LH and hCG occurring upon receptor binding were first 
demonstrated using rat gonadal cells (174). The importance of specific contact sites, such as 
the intercysteine loop sequence of both LHβ and hCGβ, was likewise demonstrated, revealing 
that the amino acid region 58-77 of these subunits is exposed on the surface of the molecule 
and participates in rat Lhr binding (175), along with Lysine residues at position 22 of hCGβ 
and 124 of both gonadotropins (176). However, it is worth of noting that the hCGα subunit 
directly interacts with the LHCGR extracellular domain (177), participating in hormone-
receptor binding, and it is not to be excluded that a similar interaction occurs upon LH 
binding. 
Informative results regarding LH and hCG binding affinity for LHCGR were provided by 
experiments evaluating the displacement of radio-labelled hCG by increasing molar 
concentrations of the hormones incubated together with membrane lysates of LHCGR-
transfected COS-7 cells (85). LH displayed an about 8-fold higher, albeit not significantly 
different, half-maximal inhibitory concentration vs. hCG (IC50; hCG IC50 = 1.7 pM; LH IC50 
= 13.0 pM), demonstrating a quite similar binding affinity for LHCGR between the two 
gonadotropins. In any case, these experiments should be repeated evaluating the displacement 
of radio-labeled LH to draw definitive and clear-cut conclusions about the binding features of 
both molecules. On the other hand, most of the current knowledge depicting the interaction 
between LHCGR and its ligands was provided by classical experiments using mutated human 
receptor or chimeric hCG. It is known that hormone β subunits contact specific amino acid 
residues of LHCGR LRRs β-strands, especially 3 and 6 (178), which play a role in the 
formation of a “sled-like” tridimensional structure typical of the gonadotropin-receptor 
extracellular domain, as well as in hormone binding and activity (179). Analysis of the 
chimeric hCG β-β dimer confirmed the need of this subunit for receptor binding, but, 
surprisingly, this dimer bound two receptor molecules with three-fold lower affinity than 
classical hCG and failed to elicit any cAMP response (180). These results demonstrate that 
the α subunit is involved in LHCGR binding and activity. In fact, experiments using an hCG 
analog, obtained by fusing the C-terminus of the α subunit and the N-terminus of the β 
subunit through a CTP fragment, confirmed that both the N- and the C-terminal portions are 
involved in receptor binding and activation (181), while the seatbelt-like structure of hCG is 
only minimally involved in LHCGR binding (182). Finally, both the α and β subunits of hCG 
possess the first three β-hairpin loops, structurally similar to those of the tumor necrosis 
factor (TNF) and the nerve growth factor (NGF), not involved in receptor binding (183). It is 
remarkable that the corresponding structures of TNF and NGF were instead crucial for 
interacting with their respective receptors. 
Interesting results were provided by mutagenesis of LHβ and hCGβ, revealing hormone-
specific biochemical features embedded in the polypeptide structure of the two molecules. 
The glutamine residue at position 74 of the β subunit plays a key role in dimer formation. 
Substitution of this glutamine with a basic amino acid residue, arginine or lysine, resulted in 
subunit association decreasing to less than 20% compared to wild-type and formation of 
inactive, mutated LH and hCG dimers which failed to induce progesterone synthesis in the 
MA-10 cell line. Interestingly, neutral (alanine) or acidic (glutamic acid) residue substitution 
at position 74 resulted in mildly (50-60%) decreased subunit association and lack of mutant 
LH binding, while mutant hCG retained full activity (184). While the amino acid residue at 
position 74 is crucial for both LH and hCG heterodimer formation, structural characteristics 
intrinsic to the protein chains result in functional differentiation between LH and hCG in spite 
of similar sequences. Most importantly, these data suggest that the two gonadotropins may 
bind the receptor differently, but further mutagenesis experiments would be needed to fully 
clarify this issue. Overall, they seem to interact similarly with the LRRs domain (185), while 
a second, less known binding site falling within position 285-354 and belonging to the hinge 
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region of LHCGR may be involved in hormone-specific contacts. Advancements were 
provided by means of a bioinformatic approach evaluating the LH- and hCG-specific 
interaction with the hinge region. In this case, an extroflexion consisting of a sulfated tyrosine 
located at position 331 (sTyr331) would play a key role in discriminating between the two 
hormones, relying on a specific spatial conformation of the receptor hinge region (Figure 3). 
The protein segment carrying the sTyr331 features a “U-shaped” structure displaying 
proximity between the amino acid sequence encoded by the LHCGR exon 10 and an adjacent 
helix. Both LHβ and hCGβ first bind the LRRs domain of the receptor. However, while 
spatial occupancy provided by hCG binding to LRRs contributes to the LHCGR 
conformational change by contacting the whole “U” structure, the smaller sized LH needs to 
interact with the sTyr331 extroflexion to induce proper conformational assembly of the 
receptor (9). Interestingly, the deletion of the amino acid sequence encoded by exon 10 would 
result in a modification of the “U” structure, consisting in the shift of the adjacent helix, 
which spatially replaces the exon 10-encoded sequence, shifting Tyr331 to a special position 
not permissive for LH accommodation. As a consequence, LH signaling would be impaired 
(85) while hCG retains its functional properties due to the preservation of the “U” structure 
binding and conformational change of LHCGR. These data were supported by experiments 
altering the exon 10-encoded sequence by introducing a double proline mutation at position 
303 and 305. In this case, disruption of the “U-shaped” structure while preserving the proper 
spatial location of the sTyr331 residue negatively impacted on hCG but not LH signaling (9). 
[FIGURE 3] 
Since LH and hCG display a specific interaction with LHCGR, different conformational 
changes of the receptor may occur, depending on the hormone. In the HEK293 cell line, co-
expression of signaling-deficient LHCGR and binding-deficient LHCGR (186) allowed 
evaluation of the ligand-induced intermolecular cooperation (53). While treatment by hCG 
was linked to full cAMP activation, LH failed to induce an intracellular increase in second 
messenger (187). hCG-induced cAMP increase was the result of binding-deficient receptor 
activation by signaling-deficient LHCGR capable of hormone binding, which relies on 
receptor dimer formation and on the ligand-receptor complex undergoing specific 
conformational changes. This is the so-called LHCGR “trans-activation" and it was suggested 
occurring under hCG treatment, while LH would be able to induce mainly self (cis)-
activation of receptors capable of hormone binding (186). These results and, in general, 
receptor cis- and trans-activation was independently supported (53,188,189), even if opposite 
results were also provided (190), questioning the concept of ligand-specific functional rescue 
between LHCGR molecules (190). 
In summary, as a result of common evolution, cross-interaction between ligands (LH and 
hCG vs murine lh, etc.) and receptors (human LHCGR, murine lhr, etc.) from different 
species may be demonstrated in vivo and in vitro, together with species-specific patterns of 
ligands for one receptor, as adaptations to maintain effective biological responses. However, 
human LH and hCG display their own specific molecular interactions with human and non-
human receptors, resulting in hormone-dependent modulation of the downstream intracellular 
signaling and physiology. This will be considered in detail in the next paragraphs. 
IV.  LH- and hCG-specific intracellular events 
LHCGR binding to its ligands triggers a number of subsequent events mediating the 
activation of multiple signal transduction pathways (1). These events start after hormone 
interaction with its high-affinity binding site located in the extracellular domain of the 
receptor, which, however, is not capable of generating intracellular signaling per se. The 
bound receptor undergoes a conformational change impacting the hinge region and 
subsequently the transmembrane domain. However, contacts between the extracellular 
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domain and loops (191), especially the second and third extracellular loops, are necessary for 
proper signaling activation. These secondary, low-affinity contacts established by the 
hormone compelled to interact with extracellular loops and the hinge region play a key role in 
signal generation (192). The spatial conformation of the activated LHCGR is linked to 
different, independently activated signaling cascades, depending on various cell-specific 
intracellular interactors of the receptor, which mainly consist of G proteins (193) and β-
arrestins (194). While the presence of LHCGR at the cell surface is linked to weak basal 
signals existing as an equilibrium between stimulatory and inhibitory signals, maximal 
production of high-affinity signal occurs upon hormone binding. 
While the intracellular events described above are overall common to all glycoprotein 
hormone receptors, the existence of ligand-LHCGR specific interactions suggests that 
qualitatively and quantitatively different patterns of intracellular signaling cascades may be 
differentially activated by LH and hCG. These features could rely on peculiar LHCGR 
conformational changes induced by ligands, as well as the presence of other interacting 
glycoprotein hormone receptors and the intracellular enzymatic milieu of target cells. All 
these factors likely contribute jointly to differentiate LH from hCG physiology. 
 Classical views and new insights on LHCGR-mediated signaling 
 Knowledge of LHCGR-mediated intracellular events progressively increased over the 
past few decades, revealing a complex picture of gonadotropin functions, not explainable 
exclusively with the old concept of steroidogenesis as the main endpoint of both LH and hCG 
functions, exerted via cAMP/PKA activation and intracellular calcium ion (Ca2+) increase. 
This classical assumption presumably originated when cAMP and steroid hormones were the 
main – or even only – molecules analyzable using the first assays available. Modern 
experimental techniques have revealed the existence of several intracellular LHCGR 
interactions and multiple signaling cascades, calling for a re-evaluation of LH- and hCG-
mediated signals. 
It is common knowledge that LH and hCG induce simultaneous increase of the second 
messenger cAMP and Ca2+ through the LHCGR (195). These two events occur relatively 
early after receptor activation, within less than one minute (196,197), and belong to two 
separate, G protein-dependent signaling pathways (198). Spatial conformation of the 
activated receptor leads to G protein stimulatory Gαs subunit dissociation from the βγ dimer, 
thus activating the adenylyl cyclase membrane enzyme, which, in turn, catalyzes the 
conversion of ATP into cAMP. This second messenger, before its metabolization to AMP by 
phosphodiesterase enzymes (PDEs), induces PKA activation and transcription factor cAMP 
response element-binding protein (CREB) phosphorylation (199). However, relatively high 
intracellular cAMP concentrations were linked to pro-apoptotic effects in granulosa cells, 
along with progesterone synthesis and androgen conversion to estrogens (200,201). In the 
theca cell, phosphorylated CREB (pCREB) binds CRE DNA target sequences modulating the 
transcription of steroidogenic enzyme-encoding genes, such as STARD1 and CYP19A1, and 
synthesis of androstenedione. Interestingly, phosphorylation of the extracellular-regulated 
kinase 1/2 (ERK1/2; pERK1/2) occurs as a downstream event to PKA activation in theca 
cells concomitant to CREB phosphorylation, inhibition of progesterone synthesis and 
stimulation of androgens synthesis, by differently modulating the transcription of genes 
encoding steroidogenic enzymes (202). Most importantly, ERK signaling is linked to 
proliferation and viability in all gonadal steroidogenic cells (203,204), as well as to anti-
apoptotic processes (205), revealing the central role of the molecule in regulating GPCR 
signals, including LH and hCG functions and reproduction. However, the activation of 
pERK1/2 is linked to several other intracellular processes following gonadotropin 
stimulation. It is required for the steroidogenic response to LH in certain cell types, such as 
Leydig cells (206), for receptor mRNA downregulation (203) and for modulating the 
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activation of GPCR kinases (GRKs) involved in receptor phosphorylation and subsequent 
internalization by β-arrestins (204). The recruitment of β-arrestins, by itself, is responsible for 
a second pERK1/2 activation (207) as a likely opposing effect to cAMP pro-apoptotic events 
mediated by GPCRs (208). 
 Gonadotropin-induced mobilization of intracellular Ca2+ was first investigated in 
hCG-treated, transfected cells expressing the murine Lhr, and was associated with PLC 
activation (209). The signaling cascade is triggered by the Gαq protein activating PLC, with 
subsequent cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol 
(DAG) and inositol trisphosphate (IP3). IP3 binds calcium channels located in the 
endoplasmic reticulum, resulting in Ca2+ release in a hormone concentration-dependent 
manner. Although both the cAMP/PKA- and the PLC/Ca2+-pathways are activated 
simultaneously, the hCG half-maximal effective dose (EC50) is 20-fold higher for Ca2+ 
mobilization than that needed for cAMP recruitment, and is independent of receptor density, 
demonstrating that LHCGR carries a dual signaling potential (210). Ca2+ binds the calcium-
modulated protein calmodulin (CaM) resulting in downstream activation of CaM kinases, 
which control cholesterol transport into mitochondria and steroidogenesis (211,212). 
Moreover, Ca2+ signaling was associated with proliferative effects in vitro (213). 
Simultaneously to these events, βγ dimer of G protein may lead to PIP2 phosphorylation to 
PIP3 by phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), thus activating protein kinase 
B (AKT). AKT might also be activated through the epidermal growth factor (EGF) receptor 
(EGFR) and exerts anti-apoptotic roles as well as inhibition of CYP19A1 expression 
(205,214), thus negatively modulating steroidogenesis, at least partially. On the other hand, 
activation of AKT as well as ERK1/2 signaling is necessary for STARD1 expression and it is 
a pathway preserved across mammalian gonads and adrenal glands of mammals to mediate 
gonadotropin- and adrenocorticotropic hormone (ACTH)-induced steroidogenesis, 
respectively (215). Taken together, gonadotropin signaling may stem from a balance between 
opposing steroidogenic and pro-apoptotic versus proliferative and anti-apoptotic intracellular 
events providing the endocrine regulation of reproduction. 
An interesting and relatively recent development consists in the dependence of the 
gonadotropin-mediated signaling on receptor concentration, due to preferential coupling to β-
arrestins/ERK1/2- and AKT-pathways at relatively low receptor density as an alternative to 
the canonical cAMP/PKA-pathway (200,216,217). These data provide a compelling, albeit 
speculative, regulatory mechanism that may contribute to differentiating gonadotropin 
signals, depending on physiological requirements. In fact, LHCGR expression is a dynamic 
event during the menstrual cycle (52) and may be associated with different LH-dependent 
roles. For instance, during the follicular and luteal phase of the menstrual cycle, the 
equilibrium between LH-driven proliferative and steroidogenic signals might be differentially 
regulated through LHCGR coupling, modulating granulosa cell proliferation, luteinization, 
androgen or progesterone synthesis. At the early antral stages, LHCGR-mediated signals 
mainly consist of the regulation of proliferative signals delivered to granulosa cells and these 
may occur as a result of unique patterns of intracellular signaling cascades, plausibly 
activated by FSHR-LHCGR heterodimers (54,169,218). The LH-dependent androgenic 
potential of ovarian follicles progressively increases together with LHCGR expression levels 
in theca cells during the late antral stage, suggesting that receptor density is linked to specific 
signaling patterns, relying on variable, LHCGR concentration-dependent Gαs protein 
coupling accompanied by increasing PLC activation (210) and cellular metabolic changes. 
These data exacerbate the specificity of LH as an irreplaceable ligand of LHCGR during 
physiological follicular phases. 
 Agonist-induced desensitization is well-known feature of LHCGR and is 
characterized by the organization of large receptor aggregates at the cell membrane (219) 
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preceding their internalization, which, in turn, is the main determinant of downregulation 
(220) regulated by GRKs, β-arrestins and other modulators (221). Interestingly, experimental 
evidences support the formation of ligand-dependent LHCGR aggregate structures, 
suggesting formation of large LHCGR complexes induced by hCG than LH binding (222). 
LHCGR aggregation may be a determinant for localization of a number of receptors within 
endosomes, in order to determine trafficking and recycling of these molecules. Persistent 
cAMP signaling may be induced by the internalized receptor forming complexes with both G 
proteins and β-arrestins (223), and suggested it is likely modulated via the adaptor protein 
interacting with pleckstrin homology domain and leucine zipper 1 (APPL1) (224). The 
molecular mechanism underlying persistent cAMP signaling is of great physiological 
relevance, since it could play a crucial role in sustaining LH functioning at mid-cycle in the 
female (218), thus bypassing the potential arrest of steroidogenic signals due to LHCGR 
downregulation. Whether hCG action is mediated through similar receptor features during 
pregnancy is unknown. A study evaluating whether LHCGR kinetics of internalization is 
linked to LH- and hCG-specific treatment by fluorescent microscopy failed to find any 
difference in human primary granulosa lutein cells (6). However, the existence of hormone-
specific LHCGR trafficking cannot be excluded since hCG displays higher potency in β-
arrestin 2 recruitment than LH, at least in the transfected HEK293 cell line (225). 
 The analysis of LHCGR-mediated signaling cascades provides a complex picture of 
intracellular events occurring upon LH and hCG binding to this receptor, suggesting that 
hormone-specific signals may occur at different levels and result in a refined, cell-specific 
modulation of the biological effect. 
 The steroidogenic pathway 
 Modulation of the steroidogenic response is of crucial relevance for the preservation 
of different physiological functions, such as gametogenesis and pregnancy, when estrogens, 
androgens or progesterone variability occur as major stage- and sex-specific products. 
Therefore, LH and hCG might be linked to different controls of the steroidogenic pathway 
regulating different, specific functions. Differences in intracellular signaling may be induced 
upon LH or hCG binding to LHCGR, likely depending on hormone-specific conformational 
changes at the receptor level (9). Since these spatial changes impact the intracellular portions 
of LHCGR, resulting in G protein activation, it is plausible that LH and hCG treatment are 
linked to activation of hormone-specific patterns of signaling pathways. In fact, mechanistic 
in vitro experiments, performed using bioluminescence resonance energy transfer (BRET) 
technology and transfected cell models, revealed lower LH- than hCG-dependent levels of 
Gαq protein activation as well as intracellular Ca2+ increase, whereas no differences in Gαs 
protein subunit recruitment and formation of dimeric or oligomeric complexes was observed 
(226). These data indicate that the hormone-induced conformation of the receptor impacts 
activation of LHCGR intracellular interactors and downstream signaling pathways. 
 Results indicative of different steroidogenic potentials related to LH and hCG were 
provided by the evaluation of cAMP production in human primary granulosa luteal cells (6), 
naturally expressing LHCGR. Dose-response experiments showed that hCG is about 5 times 
more potent than LH in inducing cAMP production, a result exacerbated by the different 
EC50 values of the two hormones (about 100 pM for hCG and 500 pM for LH). This result 
was later confirmed in transfected COS-7 and HEK293 cells (6,225), in the mouse tumor 
Leydig MLTC1 cell line (225), as well as in goat granulosa (227) and mouse Leydig primary 
cells (8), where hCG exhibited higher potency than LH in spite of different EC50s from those 
observed in human primary granulosa cells, likely indicative of cell-specific LHCGR 
expression and coupling to intracellular interactors. Interestingly, equipotent, non-saturating 
concentrations (EC50) of both gonadotropins induced similar plateau cAMP levels, reached in 
about one hour, following however different kinetics (6). In particular, LH-induced cAMP 
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response is rapid and reaches a plateau after 10 minutes, while hCG treatment requires more 
time, suggesting the existence of different regulatory mechanisms underlying steroidogenesis 
mediated by LHCGR bound to each ligand. However, the translation of in vitro data into 
physiology is not immediate, due to the several perturbing factors present in vivo, which may 
lead to biased evaluations and affect data interpretation. For instance, addition of FSH to LH 
and hCG in vitro resulted in a 5-fold increase in potency of hCG in inducing cAMP 
production, but did not have any effect on LH-specific response in human granulosa cells 
(228). This finding highlights the relevance of the co-existence of LH and FSH over the 
follicular phase of the menstrual cycle, which should not alter the FSH-mediated 
steroidogenic signal, while hCG addition to FSH administered during COS cycles might not 
lead to similar effects at the molecular level. 
 cAMP recruitment reflects the downstream pCREB activation and STARD1 gene 
expression, which is more sustained upon hCG treatment, in human primary granulosa cells 
(229), and potentiated by FSH co-treatment (228). The STARD1 gene encodes the 
steroidogenic acute regulatory protein (StAR) enzyme modulating cholesterol transport into 
mitochondria, a rate-limiting step for steroid synthesis. Since these results were corroborated 
by a greater activity of the CRE-reporter gene following hCG rather than LH stimulation, in 
both MLTC1 and transfected HEK293 cell lines (225), the higher levels of cAMP/PKA-
pathway activation obtained by hCG versus LH treatment in different cell models are likely 
driven by intrinsic characteristics of the ligand-receptor complexes, rather than cell-specific 
intracellular enzymatic environments. These data, therefore, strengthen the hypothesis that 
hCG has greater steroidogenic potential than LH, reflecting the role exerted during pregnancy 
by choriogonadotropins in supporting massive progesterone production. On the other hand, 
the dual – proliferative and androgen-stimulating – roles exerted by LH in granulosa and 
theca cells, respectively, might not require induction of the steroidogenic pathway at the 
levels necessary in pregnancy. It is reasonable that androstenedione synthesis by theca cells is 
mainly supportive for conversion to estradiol, and its levels are indeed similar over the whole 
antral phase (230). Therefore, high androgenic potential should not be required to support 
follicle growth. Interestingly, long-term (48-72 hours) treatment of granulosa cells with LH 
resulted in higher CYP19A1 gene expression compared to hCG (229), although no differences 
were found in the short-term (12-24 hours) (6). The positive action of LH on CYP19A1 gene 
expression, which encodes the aromatase enzyme, is consistent with the requirement for 
suitable estrogen production to support ovarian follicle growth. On the other hand, LH 
steroidogenic activity should be focused on oocyte growth by converting progesterone to 
androgens as well as eventually to estrogens, and on transient maintenance of the corpus 
luteum, actions requiring only limited progesterone production as a basal substrate for 
androgen synthesis. In contrast, the role of hCG in sustaining pregnancy is exerted through 
massive progesterone production, which could be exacerbated in granulosa cells by high 
levels of cAMP/PKA-pathway activation, at least in vitro (228). 
Since the collection of sufficient primary theca cells and the development of stable theca 
cell lines (231) suitable for in vitro experiments are challenging, in vitro evaluation of 
androgen synthesis is often performed using adrenal or Leydig cell lines. In the mouse 
Leydig tumor-derived MLTC1 cell line, progesterone dose-response curves produced by LH 
and hCG treatment resulted in lower EC50 and higher plateau level achieved upon hCG 
compared to LH treatment, while testosterone dose-response curves are similar and differ 
only from the LH and hCG EC50 values, reflecting the hormone potency inferred by cAMP 
data (225). In this cell model, progesterone is a precursor of testosterone and its synthesis is 
strictly connected with StAR activity, the gene expression of which is activated more by hCG 
than by LH, thereby explaining the higher, hCG-induced plateau level of progesterone. 
Although these data were obtained in Leydig cells, they corroborated hCG function in 
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pregnancy, suggesting that the steroidogenic role of hCG is focused on the control of 
efficient, massive progesterone production, which could be useless, or even 
counterproductive during the follicular phase. Instead, in the Leydig MLTC1 cell line, LH- 
and hCG-mediated testosterone production turned out to be similar and reflected cAMP data, 
suggesting that synthesis of the final steroid (testosterone) is regulated by quantitative stimuli 
and substrate availability, with no need for qualitative control of earlier events. 
 The scientific literature provides several data comparing the effects of pituitary LHs 
and chorionic gonadotropins of humans and other mammals (232,233), based on promiscuity 
of glycoprotein hormones and their receptor systems across the phyla. As a matter of fact, 
differences in cAMP production induced by human LH and hCG, and mediated by rodent Lhr 
(8,225), match those found in human granulosa cells (6,228). However, downstream LH- and 
hCG-induced pCREB, Stard1 gene expression, as well testosterone synthesis are all highly 
similar, in mouse primary Leydig cells, in vitro (8). This effect may be the result of a balance 
between stimulatory and inhibitory signals obtained by treatment with human gonadotropins 
through the cAMP/PKA- and ERK1/2-pathways. Most importantly, these data indicate that 
only a quantitatively, but not qualitatively different intracellular response occurs in rodent 
primary Leydig cells. This is likely due to their enzymatic equipment, capable of triggering 
testosterone synthesis like an “on/off switch”, more than discriminating between 
steroidogenic and proliferative signals, as occurs in granulosa cells. This concept may find 
support in observations recently described in a case-report. In a hypogonadic, 
hypophysectomized man sequentially treated by LH and hCG (234), both gonadotropins 
showed similar efficacy in inducing testosterone production. 
The inconsistency between human granulosa and rodent Leydig cells may be due to 
differences in amino acid sequences between LHCGR and mouse Lhr: they share only 80% 
identity at the hinge region (8), which is responsible for discriminating of LH- and hCG-
mediated signaling (9), suggesting that the evolutionary divergence between the two species 
impedes the qualitative discrimination of intracellular signals mediated by human hormones 
despite effective receptor binding. These data provide relevant insights for the so-called “Van 
Hell” in vivo bioassay (165), currently used for inferring gonadotropin dosages for clinical 
purpose in humans by only evaluating testosterone-dependent endpoints (235,236). In vivo 
bioassays aim to assess the biological activity, measured in terms of organ weight gain, of 
pharmacological preparations injected into living rodents. However, these assays might not 
be appropriate for detecting the full spectrum of gonadotropic bioactivity mediated by 
LHCGR in human cells. 
Taken together, LH and hCG retain different steroidogenic potentials modulated in a cell-
specific manner. While a qualitative discriminatory capability between LH- and hCG-
mediated signals is displayed by granulosa cells, steroidogenesis, mainly androgen 
production, in Leydig and theca cells is regulated by quantitative signals. These data 
highlight the specific roles for each gonadotropin in their target cells, providing experimental 
evidence that LH and hCG are not equivalent. 
Proliferative and pro-apoptotic signals 
 Proliferative signals control antral follicle growth in the presence of both FSH and LH 
(169), while hCG physiologically acts on LHCGR-expressing cells dedicated to progesterone 
synthesis. Pregnancy is also characterized by angiogenic events, consistent with cell 
proliferation and possibly mediated by hCG-H, growth factors and steroids. It is however 
plausible that LH and “classical” hCG differentially impact cell proliferation, given the 
specific molecular properties required to optimize follicle growth and massive progesterone 
production. Discrimination of qualitatively different LH- and hCG-mediated signaling by 
LHCGR was demonstrated in human primary granulosa lutein cells by assessing activation of 
phospho-proteins. Both gonadotropins showed maximum activation of ERK1/2- and AKT-
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pathways at a concentration of 100 pM, resulting, however, in a hormone-specific 
phosphorylation pattern of these kinases (6). LH treatment resulted in higher and more 
sustained pERK1/2 and pAKT activation compared to hCG (6,229), reflecting the 
proliferative and anti-apoptotic roles (237,238) exerted by LH during the antral phase of 
follicular development. Moreover, the range of effective of LH concentrations is widened by 
presence of FSH combined with LH, but not with hCG, confirming that gonadotropin-
specific activities are potentiated upon FSH co-treatment (228). Interestingly, LH and hCG 
displayed different ratios between the cAMP EC50 and the maximally activating 
concentrations required for pERK1/2 and pAKT activation (about 5:1 for LH and 1:1 for 
hCG), in granulosa cells. These data suggest that LH has a higher proliferative and anti-
apoptotic potential than hCG, in granulosa cells in vitro. This is an example of biased 
signaling, consisting of activation of different intracellular endpoints evoked by varying 
concentration and ligand. 
Expression of proliferative and anti-apoptotic genes, in granulosa cells, reflects hormone-
specific signal transduction. The expression of growth-promoting AREG gene (6), which 
encodes epidermal growth factor (EGF)-similar amphiregulin, and of the CCND2 gene (229), 
encoding cell cycle regulator, G1/S-specific cyclin-D2, is upregulated more by LH than hCG. 
In contrast, the high steroidogenic potential of hCG, which relies on efficient cAMP 
production, is linked to expression of pro-apoptotic genes, in primary granulosa cells in vitro, 
especially in the presence of FSH. Although both LH and hCG elicited increased TP53 pro-
apoptotic gene expression, the procaspase 3-encoding gene CASP3 was positively modulated 
upon hCG treatment, while LH fails to obtain similar results, likely due to upregulation of the 
anti-apoptotic X-linked inhibitor of apoptosis protein-encoding gene XIAP (228). This 
finding should be confirmed in other cell types. However, gene expression data supported a 
dose-dependent cell viability decrease in human granulosa cells maintained 24-72 hours 
under hCG stimulation in vitro, whereas LH resulted in the opposite effect by counteracting 
cell death (228,229). Similar conclusions were drawn from a study comparing the long-term 
effects of LH and hCG in goat granulosa cells in vitro. While hCG induced relatively high 
cAMP intracellular levels and reduced cell viability, LH treatment resulted in marked 
phosphorylation of ERK1/2 and increased rate of cell proliferation (227). 
 Whether hCG is capable of mediating pro-apoptotic effects in vivo, at least during the 
follicular phase of the menstrual cycle, should be investigated in-depth, since the molecule 
was associated with both proliferation and inhibition of cancer cell growth (239,240), and 
given the proliferative role exerted during placentation. It is plausible that hCG-dependent 
life signals are cell-specific and sensitive to a particular hormone isoform or glycosylation 
variant (153). Anyway, proliferative and anti-apoptotic signals should be transmitted through 
ERK1/2- and AKT-pathways (151,241), which are preferentially activated by LH, rather than 
hCG, at least in human primary granulosa cells in vitro. Interestingly, hCG displayed higher 
efficiency in recruiting β-arrestin 2 than LH, which has a 13-fold higher EC50 (hCG EC50 
about 10 nM, LH EC50 130 nM) and even acts as a partial agonist, not reaching hCG-
dependent plateau levels (225). Although these data were obtained in the MLTC1 cell line, 
they are likely to also be valid in human granulosa cells, since the recruitment of β-arrestins 
is dependent on GPCR activation by agonists (242). Most importantly, these data reflect the 
lower efficacy and efficiency of LH compared to hCG in inducing progesterone production, 
indicating that β-arrestins are involved in steroidogenesis, as demonstrated by decreased 
progesterone levels upon depletion of β-arrestins by siRNA probes (225). β-arrestins are 
involved in ERK1/2 phosphorylation and GPCR internalization (208), as well as proliferative 
signals in granulosa cells (200). It is conceivable that relatively high amounts of LH would be 
required to down-regulate the LHCGR-mediated steroidogenic and pro-apoptotic signaling 
(243), in light of the less efficient cAMP production induced by LH as compared to hCG. 
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These data support the idea that LH has greater proliferative potential than hCG, at least in 
granulosa cells, reflecting its physiological function as follicle growth regulator (Table 3). 
[TABLE 3] 
Cross-talk between gonadotropin- and steroid hormone-mediated signaling 
 The effect of LH and hCG on signal transduction may precisely be revealed by in 
vitro experiments, where perturbations and interactions between signaling pathways activated 
by different hormones and paracrine factors are missing. For instance, pro-apoptotic effects 
linked to hCG addition were hardly reproduced in ART cycles in vivo, and showed weak 
effects or even antithetical results (244,245). This concept is also valid for cancer cell growth 
(239,240), which may be both positively or negatively susceptible to the presence of the 
hormone, depending on the cell type. Therefore, intracellular effects clearly dissected in vitro 
may be masked in vivo. 
In the gonads, LH and hCG induce steroid hormone production, activating the same 
pattern of intracellular signaling cascades. Steroid compounds, such as glucocorticoids, have 
been associated with proliferation of granulosa cells, as well as protection against cAMP- and 
p53-induced apoptosis (246). These molecules act through activation of pAKT and pERK1/2 
counteracting intracellular death signals. During the follicular phase of the menstrual cycle, 
gonadotropin functions converge in production of progesterone, which is further converted to 
androgen in theca cells. Androgen is transferred to granulosa cells, where it is transformed to 
estrogen, leading to potent proliferative effects and inducing follicle growth in vivo. Indeed, 
estradiol activates the AKT-pathway in vitro (247), and estrogen receptor-beta (ERβ) 
knockout mice are characterized by impaired follicular development (248). It is reasonable 
that estradiol could counteract pro-apoptotic signals mediated by high cAMP intracellular 
levels, obtained during treatment by FSH and hCG administration in COS. This concept was 
confirmed in vitro by adding estradiol to hCG or LH treatment of human granulosa cell 
cultures (229). The effect of steroid addition is predominant on that of either LH or hCG 
alone, triggering high levels of pAKT activation, preventing hCG-dependent procaspase 3 
cleavage and decreased cell viability. This molecular mechanism may explain why hCG 
addition to FSH in COS for ART is associated with multiple follicular development, 
reasonably sustained by high estrogen levels and avoiding natural follicular atresia. 
Progesterone is the main steroid produced during the luteal phase, as well as by human 
primary granulosa lutein cells in vitro, and it is responsible for the protection from apoptosis 
linked to hCG treatment (249). On the other hand, it is well known that both LH and hCG, as 
well as progesterone, promote ERK1/2 and AKT phosphorylation. They also induce 
expression of AREG and epiregulin-encoding gene EREG, two EGF-like ligands with 
positive effects on granulosa lutein cell viability in vivo and preservation of the corpus luteum 
in primates (250) and rodents (251). The same intracellular pathways lead to the growth of 
progesterone receptor-expressing cancer cells (252), strengthening the evidence for 
proliferative and anti-apoptotic effect mediation by steroid hormones through activation of 
signaling cascades common to gonadotropins. These data support the tumorigenic potential 
described in hCGβ-overexpressing transgenic mice, where human gonadotropin and high 
levels of progesterone may co-assist the development of multiple cancers (253,254). 
However, since extragonadal tumors were totally abolished by ovariectomy in these mice, it 
is plausible that the tumorigenic potential of hCG is exerted through aberrant ovarian 
functions, rather than by a direct gonadotropin effect (7). Interestingly, the apoptotic effect 
seems to be directly dampened by hCG treatment in Leydig cells (255), where signals 
induced by both LH and hCG converge on a similar balance between cAMP production and 
ERK1/2 phosphorylation, as well as downstream steroidogenesis (8), suggesting the different 
nature of LHCGR-mediated signaling within testis and ovary (Figure 4). 
 [FIGURE 4] 
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V. Polymorphisms and mutations 
 Several single-nucleotide polymorphisms (SNPs) and mutations falling within 
gonadotropins and their receptor genes have been described (20,256). They may modulate or 
impair hormonal response or receptor function, impacting reproductive function or leading to 
disease. Generally, spontaneous mutations occur as random events and are silent, not 
resulting in amino acid changes at the protein level. Some of them however cause changes in 
the amino acid sequence and are linked to clinical phenotypes. SNPs instead result in mild 
phenotypes without strong repercussions on reproductive success of individuals. They have a 
frequency ≥1% in a given population and contribute to the endocrine ethnic background. 
Most SNPs and mutations impacting LH and hCG signaling are carried by LHCGR (257). 
Among the several SNPs and mutations falling within the LHB/CGB gene cluster, only a 
few of them have been associated with specific phenotypes. A better understanding of the 
consequences of LHβ and CGβ mutations is provided by the study of transgenic mice models. 
The LHB gene knockout male mice presented hypogonadism, with low testosterone levels 
and hypoplastic Leydig cells, yet displayed normal serum FSH levels, while female mice 
were infertile and featured anovulation and degenerated antral follicles (258). The mouse 
phenotype partially matches clinical observations in humans, where LHB gene mutations lead 
to a severe, eunuchoid phenotype in males (259). Mouse models may therefore not provide a 
full comprehension of human LH physiology. Administration of exogenous FSH is enough to 
sustain follicular development and ovulation in hypophysectomized female mice, while this 
hormone fails to do the same in Lhr knockout mice (260). These findings support the concept 
that the presence of gonadotropin receptors, rather than LH, is required to sustain 
gametogenesis in mice. Transgenic mice overexpressing both the CGB and the CGA subunits 
were expected to replicate the human phenotype linked to activating mutations of LHCGR, 
consisting of asymptomatic women and men developing precocious puberty and testis 
tumors. Surprisingly, these mice featured the opposite phenotype, with a normal phenotype in 
males, while precocious puberty, obesity and luteinized ovaries with luteomas and 
hemorrhagic cysts were present in females (7). 
Altogether, while transgenic mice may not be fully representative of human physiology, 
they provided new insights to comprehend LH/hCG- and LHCGR-specific functions 
emerging from clinical data involving SNPs and mutations described below. 
 LHβ and hCGβ polymorphisms 
 Few LHB and CGB gene polymorphisms were studied in conjunction with their 
clinical phenotype. Overall, they do not severely impact fertility and most of them lack 
molecular characterization in vitro, not providing clear insights of their suggested effects in 
vivo. One exception is provided by the most common LHB gene variant (V-LH), which was 
discovered in the Finnish population, which displays a double polypeptide change, namely 
tryptophan to arginine at position 28 and isoleucine to threonine at position 35 of the amino 
acid chain (261,262), and introduces a glycosylation site (263) hiding the molecule from a 
specific anti-LH antibody (264). V-LH exhibited reduced serum half-life and bioactivity in 
vivo compared to wild-type LH, as well as decreased receptor binding activity and potency 
for progesterone production in vitro (265), and induced preferential IP3-related signaling, 
rather than cAMP/PKA (266). Perturbation of the signaling cascade by V-LH might impact 
granulosa cell survival and follicle development. In cumulus cells of heterozygous women 
undergoing ART, high levels of apoptotic markers were found, such as DNA fragmentation 
index and cleaved caspase-3, and they negatively influenced the success rate of 
intracytoplasmic sperm injecton (ICSI) procedures (267). However, increased expression of 
this variant, identified by SNPs within the promoter region in linkage disequilibrium, 
resulting in an about 40% higher activity compared to that of the “normal” LHB promoter, 
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compensates for the weaker hormone bioactivity (268). The frequency of V-LH was lower in 
obese women affected by polycystic ovary syndrome (PCOS) than in healthy and non-obese 
PCOS women, suggesting that V-LH may provide protection from developing symptomatic 
PCOS in obese women (269). Nonetheless, this LH variant was associated with infertility in 
homozygous Japanese women (270), while Baltic, V-LH carrier men affected by idiopathic 
infertility have higher serum LH levels than healthy men (271). Interestingly, V-LH was 
found in a 18-year-old man affected by the fertile eunuch syndrome (272). This patient 
displayed hypogonadism and normal responses to treatment by exogenous GnRH and hCG. 
Overall, however, the ethnicity-related clinical features displayed by V-LH and the mild 
phenotypes suggest that it simply represents an example of phenotypic variations due to 
genetic polymorphisms as the basis of human diversity. 
A SNP (rs1056917) in exon 3 of the LHB gene was found more frequently in South 
Indian PCOS women (273). This SNP is characterized by the synonymous amino acid change 
“T” to “C” at position 294 of the gene sequence. Its contribution to PCOS pathogenesis is 
thus unexplained. It is conceivable that the polymorphism might impact on the expression or 
functions of other molecules, since it falls within the palindromic RUVBL2 gene sequence, 
encoding for a protein interacting with the activating transcription factor 2 (ATF2/CRE-BP1) 
(274). Several other SNPs falling within or close to the LHB gene sequence were found to be 
associated with central precocious puberty (275) or infertility (276) in women, but their 
contribution in defining the endocrine phenotype should be evaluated together with other 
polymorphisms related to hormones and their receptors. Moreover, these results should be 
independently confirmed in other populations and supported by functional in vitro data, 
which is still lacking. 
Among the CGB genes SNPs and mutations previously described in association with 
miscarriage (41) and mentioned in the chapter “hCGβ isoforms and glycosylation variants”, a 
polymorphism falling within the CGB5 gene displayed inefficient assembly when co-
transfected with the CGA gene in the Chinese hamster ovarian (CHO) cell line. This naturally 
occurring variant is associated with infertility in women and is characterized by a valine to 
methionine exchange at codon 79 (277). Seventy-one hCGβ variants deriving from CGB5 
and CGB8 genes might be predictive of recurrent miscarriage in European populations (278), 
suggesting the relevance of these transcripts in sustaining pregnancy. Moreover, since 
heterozygous haplotypes calculated for these SNPs are relatively frequent, they may be 
subjected to balancing selection in Europeans. Overall, associations between CGB gene SNPs 
and miscarriage are relatively rare and molecular mechanisms supporting clinical data are 
unclarified.  
In general, as in the case of SNPs and common variants in other genes, SNPs in LHB and 
CGB genes are unlikely to be major determinants of diseases. Rather, they contribute to 
human phenotypic variation and, together with other SNPs, may be relevant in discrete 
genomic clusters associated with particular reproductive problems, e.g. PCOS (279). 
LHβ and hCGβ mutations 
Possibly because of the physiological role played in a specific time-window and in one sex 
only, inactivating hCG mutations are rare and, presumably, incompatible with successful 
pregnancy. Indeed, one of the first mutations affecting hCG function was somatic and was 
found in the α subunit secreted by undifferentiated carcinoma cells of the femoral region 
(280). This mutation consisted of a substitution of glutamic acid by an alanine at position 56, 
which changed the hydrophobic profile of the molecule, resulting in misfolding and 
impairment of dimerization with the β subunit. Similar effects at the molecular level have 
been associated with a genomic CGB5 gene mutation leading to a valine to leucine swap at 
position 76 of the β subunit (281). The mutated hCGβ is only capable of 10% dimeric 
assembly yet shows increased potency in inducing cAMP production. Nevertheless, enhanced 
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steroidogenic signaling was not sufficient to replace loss of function due to impaired 
dimerization, as this mutation was found in a Northern European patient affected by recurrent 
miscarriage. CGB8 gene mutations have also been described and found in individuals of the 
same population (281), albeit without a link to pathogenic phenotypes. A proline to arginine 
change in position 93 resulted in two-fold reduction in the β subunit secretion without 
affecting its biological activity, while no effects were associated with an arginine to 
tryptophan substitution at position 28. Altogether, these data indicate that genomic mutations 
within the genes encoding for the two major hCG transcripts result in mild consequences that 
can be tolerated. 
While mutations in the CGB genes predominantly result in miscarriage, mainly due to 
misfolding of the β subunit and impaired dimer formation (281), LHB gene mutations result 
in phenotypes featuring hypogonadism, decreased or impaired spermatogenesis, delayed 
puberty and low testosterone levels in males, and amenorrhea in females. Such symptoms 
might be associated with infertility in both sexes and may be due to disruption of LHB splice 
sites (259) or in the signal peptides (282). Mutations disrupting the cystine knot motif, such 
as a glycine to aspartic acid mutation at position 56 may result in defective heterodimer 
formation, undetectable serum LH levels and hypogonadism (283). A similar phenotype was 
described in a patient carrying a lysine deletion at position 40 of LHβ, which impaired release 
of hormone dimers (284). Since mutations falling within the LHB gene do not impair receptor 
function, long-term administration of exogenous hCG to these patients induces virilisation 
and testicular growth, testosterone synthesis and spermatogenesis, in conjunction with 
fertility (285). Interestingly, these data strengthen the hypothesis that LH and hCG may be 
equivalent in inducing proper Leydig cell function and fertility, which mainly relies on 
testosterone synthesis in males and might be switched on by an on-off molecular mechanism, 
rather than qualitatively different hormonal signals (8). In this case, it cannot be excluded that 
signaling cascades are maximally activated by low amounts of occupied receptors, 
confirming prior findings in rodent’ Leydig cells in vitro (166). In fact, certain mutants of 
LHβ may display residual in vitro activity sustaining low testosterone synthesis, but enough 
to support normal spermatogenesis and fertility (286). Studies in siblings carrying the same 
LHB mutations totally disrupting LH signaling, revealed different, sex-specific clinical 
effects. While normal pubertal maturation may be conserved in women, this is not the case in 
men (282), suggesting that, in women, the regulation of estrogen production needs to be 
sustained by FSH acting on granulosa cells, supported by basal androgen production 
originating from theca cells. Moreover, in the ovary, LH-mediated signals might plausibly be 
driven by LHCGR-FSHR heterodimers activated by FSH upon the onset of puberty, as well 
as during early antral follicular stages (169), while Leydig cells are the only LH target and 
source of proper testosterone levels required to support male secondary sex characteristics. 
Nevertheless, inactivating mutations of LHβ subunit have been associated with ovulatory 
disorders (287), suggesting the fundamental relevance of proper LH signaling for the ovarian 
cycle. 
Receptor mutations and polymorphic variants 
Although several SNPs were found within the LHCGR gene, their contribution in 
determining clinical phenotypes is mostly weak. An exon 10 SNP, p.N312S (rs2293275), was 
found in association with spermatogenic damage and is highly prevalent among infertile male 
patients (288). However, while the number of LHCGR marker SNPs impacting male 
reproductive function is very low, it is remarkable that the very gene is a genetic hot spot for 
polycystic ovary syndrome (PCOS) in Han Chinese population (289). 
A common polymorphism of LHCGR consists of the addition of two amino acid residues, 
a leucine (L) and a glutamine (Q), at codons 19–20 within exon 1, originating from a 
CTCCAG insertion at positions 55–60 of the gene (290). This receptor variant, known as 
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“ins18LQ,” is common among Caucasians but absent in other populations, such as Japanese. 
Although the double-amino acid residues insertion does not severely affect the LH- and hCG-
mediated cAMP production, the polymorphism is linked to a more active signal peptide and 
to an adverse outcome in breast cancer patients (291). 
The LHCGR gene mRNA variants comprise highly expressed, primate-specific transcripts 
including a cryptic exon located between the sixth and seventh exon with unknown function 
(292). This exon is named “6A” and is responsible for three different mRNA receptor 
variants differing in length based on the location of stop codons. The resulting mRNA 
variants, in addition to the “classical” LHCGR, include two truncated forms consisting of 
exons 1 to 6 and one “6A” of different length, and a full-length transcript with exon “6A” 
between exons 6 and 7. Mutations falling within this region are causative of aberrant gene 
transcription leading to Leydig cell hypoplasia type II (293), while SNPs in exon “6A” were 
associated with testosterone levels in male infertile patients (294). Especially, levels of this 
hormone were more elevated in “G” homozygous men than in those carrying the “T” allele of 
the exon “6A” SNP rs68073206. Interestingly, mutations of this cryptic exon were discovered 
for the first time in 46,XY patients affected by sex development disorders and characterized 
by female phenotype, a blind-ending vagina and primary amenorrhea (292). Based on current 
knowledge of human testis development, the presence of testicular structures, along with a 
phenotype largely resembling testicular feminization (which is due to the lack of androgen 
action), suggested that the patient was not at all responsive to endogenous LH and maternal 
hCG. Therefore, it is plausible that isoforms deriving from exon “6A” may be linked to the 
discrimination between hCG- and LH-mediated signals. Since our knowledge about the 
control of human testicular development by fetal pituitary LH or maternal hCG is limited and 
provided by individuals affected by genomic mutations and data from non-human mammals, 
the putative role of exon “6A” in discriminating LH and hCG remains unclear. 
Interesting data on LH- and hCG-specific functions were provided by the deletion of the 
LHCGR exon 10-encoded sequence, described in the chapter “Evolutionary convergences: 
trophoblast LH and pituitary CGs”. As discussed above, the mutated receptor is capable of 
transmitting hCG, but not appropriate LH signals in spite of binding both hormones (85), 
resulting in  male hypogonadism with  normal male phenotype (84). The clinical evidence 
derived from naturally occurring mutations or deletions of LHCGR exons 6A and 10 
demonstrate that these sequences of the receptor are essential for LH and hCG action and 
may be instrumental in discriminating between the two hormones, although the mechanism 
remains largely unknown.  
VI. Pathophysiology of LH and hCG 
 Specific profiles and levels of LH and hCG may be associated with pathological 
conditions, such as hypogonadism, cancer and endocrine disorders. These effects may be due 
to excessive or low hormone activity, altering normal physiology and leading to a wide range 
of clinical phenotypes. Since gonadotropins modulate cell growth, it is reasonable to assume 
that their action is linked to proliferation of cancer cells and tumorigenesis. Moreover, extra-
gonadal action of LH and hCG may produce clinical effects. For instance, pregnancies of 
fetuses affected by trisomy 21 are typically characterized by high levels of hCG in maternal 
serum, in spite of low hCG synthesis capability by the placenta (295). This apparent paradox 
may be caused by high activity of sialyltransferase-1 and fucosyltransferase-1 enzymes in 
trisomy-21 trophoblast cells, resulting in highly glycosylated and acidic hCG molecules, 
displaying reduced activity in vitro. hCG synthesis peaks at around 10 weeks in trisomy-21 
pregnancies and declines to lower levels than in chromosomally normal pregnancies. In any 
case, since no association between sialylated hCG isoforms and trisomy-21 pregnancy were 
found (296,297) while fucosylation was even not investigated, any conclusion should be 
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interpreted carefully. However, highly glycosylated molecules are more persistent due to 
increased half-life (295). Moreover, high hCG levels during pregnancy may induce aberrant 
expression of LHCGR in adrenal glands of the mother, resulting in the increased risk of 
adrenal hyperplasia and transient Cushing syndrome due to cortisol release in response to the 
hCG-induced signals (298). Several other clinical effects related to aberrant LH and hCG 
signaling, i.e. hypogonadism, precocious puberty, PCOS, miscarriage and cancer, are 
described in this chapter. 
Hypogonadism and precocious puberty 
Hypogonadism is a pathology characterized by decreased gonadal activity and hormone 
production, and may be caused by impairment of LH-mediated signaling (299). In males, the 
disease may arise from testis (primary) or from dysfunction of the hypothalamic-pituitary unit 
(secondary or central hypogonadism) (300), although several hypogonadal patients remain 
idiopathic, suggesting a possible polygenic nature (301). The phenotype associated with an 
impaired HPG axis may vary depending on the severity of the disease. Most severe cases may 
be linked to rare autosomal recessive conditions, such as inactivating LHCGR mutations, 
typically interfering with the development of male external genitalia and testicular descent, 
and resulting in phenotypically female, 46,XY patients with Leydig cell hypoplasia type 1. 
They are unresponsive to both endogenous LH and exogenous hCG administration and are 
characterized by primary hypogonadism and sexual differentiation disorder, featuring the 
absence of Leydig cells, lack of masculinization and pubertal maturation with female-like 
phenotype and external genitalia. Milder phenotypes could be linked to LHB mutations 
affecting hormone functioning, resulting in infertile individuals with male external genitalia 
and maldescended testes, micropenis and/or hypospadias. In this case, given the presence of a 
functional LHCGR, hCG therapy showed efficacy in inducing testosterone production and 
may restore fertility. The clinical picture is strictly connected to testosterone levels, 
insufficient to support male sexual development. The total blockade of Leydig cell function is 
largely attributed to mutations impairing receptor transport to the cell membrane (302) and 
activation of the G protein-dependent signaling cascades (303), but mutations affecting LH 
binding have also been described (304). An inactivating, homozygous mutation was found in 
a 46,XY hypogonadic patient with delayed puberty, normal prepubertal male phenotype and 
descended testes, displaying a glutamine to arginine substitution at codon 54 of LHβ (305). 
The resulting β subunit was capable of forming a heterodimer with the α subunit but failed to 
bind the receptor in vitro. This patient was treated with long-term hCG administration, 
resulting in testicular enlargement, virilisation and spermatogenesis. Similar phenotypes and 
histories were found in consanguineous, hypogonadic patients bearing the deletion of lysine 
at position 40 of the LHβ, linked to intracellular retention of the hormone (284). These data 
allow for the comparison of the effects of mutations impairing LHCGR or LHβ functions in 
the male. While the first are linked to severe, female-like phenotypes, LHβ mutations are 
compatible with male phenotype and exogenous hCG-induced spermatogenesis (306). Taken 
together, these findings suggest that maternal hCG, together with the presence of intact 
LHCGR, can, at least in part, compensate the absence of fetal pituitary LH and support the 
development of a male phenotype, although the presence of maldescended testis and 
micropenis suggest that proper production of functional LH molecules is required to fully 
support secondary sex characteristics. 
Inactivating mutations falling within the LHB gene were described in infertile females, 
where the phenotype displayed normal external genitalia and spontaneous breast and pubic 
hair development at puberty. Menarche was delayed or even normal, yet these patients were 
oligo-amenorrhoic and characterized by failure in achieving ovulation and normal LH, 
estradiol and progesterone levels in the ovulatory or luteal phase. Since women with LHB 
mutations have functional LHCGR, they may successfully be treated with LH or hCG (304), 
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differently from hypogonadic women with LHCGR inactivating mutations, which are 
unresponsive to gonadotropin treatment. 
Precocious puberty is defined as the onset of puberty at a relatively young age and may be 
determined by several factors, such as hypothalamic or pituitary dysfunctions, McCune-
Albright syndrome or sex hormone-secreting tumors. LH signaling is one of the factors 
regulating the onset of puberty. However, while LHCGR activating mutations, resulting in 
sustained tonic cAMP production due to an aberrant ratio between the Gαs (stimulating) and 
Gαi (inhibitory) protein activation (307), were linked to familial, male-limited, precocious 
puberty, no phenotype is observed in females. No LHβ mutations are known to cause 
excessive LH activity. 
Polycystic ovary syndrome 
PCOS is a common endocrine disorder affecting 5-20% of women worldwide and defined as 
the coexistence of at least two out of three typical features: polycystic ovaries, ovulatory 
dysfunction and hyperandrogenism (308). Other symptoms may occur in association with the 
disease, such as type-2 diabetes, metabolic syndrome, adrenal dysfunction, obesity and/or 
insulin resistance (309). Since PCOS has likely maintained an overall constant prevalence 
over centuries, albeit being linked to anovulatory subfertility, it has been addressed as an 
evolutionary paradox (310,311). Intralocus sexual conflict was proposed to explain the 
persistence of genetic loci linked to increased reproductive success in males in conjunction 
with a risk of developing the disease in females (279,312). In fact, PCOS has a polygenic 
nature and genome-wide association studies (GWAS) found both FSHR and LHCGR genes to 
be two of several hot spots for the disease (313,314), suggesting the relevance of 
gonadotropin signaling in its pathogenesis. However, endocrine disrupting chemicals 
modulating sex hormone-dependent signals might be associated with the disease (315). 
Hyperandrogenism is a major determinant of the disease and is indicative of excessive 
androgens produced by theca cells, exposed to relatively high LH levels. Moreover, androgen 
and estradiol response to FSH stimulation is higher in PCOS than in healthy women, 
suggesting that molecular mechanisms regulating paracrine signals between granulosa and 
theca cells are amplified in individuals carrying the disease (316). As a consequence of high 
estrogen levels, the feedback mechanism regulating pulsatile gonadotropin production is 
altered in PCOS women, resulting in low FSH levels, a high LH:FSH ratio and impairment of 
follicle selection and ovulation (317). In humans, cyclic gonadotropin production recover 
following treatment with the estrogen receptor antagonist clomiphene citrate, which 
temporarily restores proper feedback mechanisms at the pituitary level (318). Polycystic 
ovaries and adrenal disturbances are recapitulated in the phenotype of transgenic, LH-
overexpressing female mice, supporting the role played by this hormone in PCOS 
pathogenesis (319). Interestingly, hCG-overexpressing female mice displayed a slightly 
different ovarian phenotype, characterized by multiple corpora lutea and enhanced estradiol, 
progesterone and testosterone levels, along with prolactin-linked adenomas (7). Different 
phenotypes of female mice overexpressing LH and hCG strongly support the view of a 
different in vivo action of these two gonadotropins in rodents. 
The polycystic ovary appearance is one of the characteristics which may be used for the 
diagnosis of PCOS and consists of the recruitment of several follicles reaching the antral 
stages without completing maturation. Provided that LHCGR is of central importance for the 
understanding of the disease, theca cell androgenic functions and granulosa cell proliferation 
are modulated by different genes (320), such as DENND1A, INSR and RAB5B, whose 
functions are involved in modulating proliferative signals through the activation of AKT- and 
ERK1/2-pathways. The activity of these kinases is increased in the ovary of PCOS women 
(321) and this picture is compatible with exaggerated LH-, as well as estrogen-dependent 
stimuli. Interestingly, SNPs falling within the LHB gene may be linked to increased PCOS 
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risk as well. This is the case of the two SNPs inducing a tryptophan to arginine change at 
position 28 and an isoleucine to threonine change at position 35 of LHβ (322), which are in 
linkage disequilibrium and might contribute to elevated testosterone levels in Brazilian PCOS 
women. Moreover, it was suggested that the V-LH variant might have been a contributing 
factor in the development of the disease in a Japanese woman (323), although another study 
failed to find a similar association in Turkish women (324). This issue should be further 
investigated and independently confirmed in other populations, it is nonetheless suggestive of 
altered functioning of proliferative and androgenic LH activity. Most importantly, the 
glycosylation profile of LH molecules may change depending on steroid hormone levels, 
influencing gonadotropin activity (325). Although the molecular mechanism underlying the 
control of biologically active LH isoform production by the pituitary is unknown, age-
specific profiles of LH glycosylation were reported among PCOS women. Notably, mainly 
alkaline LH species were found in adult PCOS patients (326), while basic isoforms featuring 
high in vitro activity were predominant among adolescent girls affected by the disease and 
positively correlated with androgen levels (327). It is plausible that highly bioactive LH 
isoforms result in elevated androgen levels and this hypothesis is consistent with the 
inhibition of steroid synthesis by GnRH antagonists in PCOS women (328). 
Given their chronic overexposure to “LH activity”, PCOS women require particular 
attention when ovarian stimulation by exogenous gonadotropins is required in the framework 
of ART. Coherently with the presence of high estradiol levels and the development of excess 
antral follicles, which may lead to excessive response to gonadotropin stimulation (316), 
PCOS women may have an increased risk of developing ovarian hyperstimulation syndrome 
(OHSS) and multiple pregnancies in ART (329). Thus, ovulation induction with a GnRH 
agonist has been proposed as a better choice than hCG (330,331), consistent with the high 
steroidogenic potential of the choriogonadotropin, which may be linked to OHSS. However, 
the matter is still under debate and the clinical symptomatology spectrum related to PCOS 
together with ovarian morphology may be a determinant for response to hCG exposure (332), 
even in pregnancy, when levels of endogenous free hCGβ molecules differ between healthy 
and PCOS women (333). Interestingly, a clinical study comparing ART performance between 
Caucasian and Yoruba women from Western Nigeria, triggered by hCG, revealed higher 
estradiol levels and prevalence of symptoms typically related to polycystic ovarian syndrome 
among African females, who are more exposed to an increased risk of OHSS and twin 
pregnancies. This finding suggests that ethnicity could be a determinant for PCOS. The 
anovulatory condition linked to the disease may lead to maintenance of follicular reserve for 
a longer time as compared to healthy women and this concept is corroborated by the 
converging effects of genes regulating the age of menopause and LH levels (334). PCOS 
could therefore be viewed as an evolutionary strategy to prolong the fertile window at the 
cost of a decreased number of ovulatory cycles (335). Although suggestive, this hypothesis 
should be discussed further, since no evidence of evolutionary advantages was 
experimentally demonstrated and subfertility linked to PCOS may result in significant effects 
in modern times. Today, especially in Western society, fertility and pregnancy are sought at a 
relatively late reproductive woman age (20) and ovarian stimulation may be performed in the 
framework of ART using commercial hormone preparations, a setting quite different from a 
natural cycle in a non-medicalized society. 
Miscarriage 
Most miscarriages occur within the first trimester of pregnancy and are mainly due to 
placental or fetal abnormalities. Embryo aneuploidies are typical causes of miscarriage (336) 
and other clinical conditions, such as diabetes and obesity may be risk factors for poor 
pregnancy outcomes (337). These data point out the importance of proper metabolic and 
endocrine function in regulating embryo implantation and development. The action of LH is 
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central in follicle growth and uterus preparation, while hCG is required to support pregnancy, 
and both these aspects impact pregnancy success. A dual function might be assumed for LH 
action: it is linked to estrogen-mediated proliferative events in the uterine epithelial cells 
during the follicular phase, resulting in increased endometrial thickness, while it becomes 
mainly steroidogenic during the luteal phase, when the increase in progesterone levels is 
associated with the secretory action in the uterus. These changes of steroidogenic potential 
are accompanied by the 1 to 100-fold increase of LHCGR expression, from the early antral 
stage up to ovulation (52), and are very intense in the corpus luteum (338). Antral follicle 
growth requires proliferative signals preferentially and directly exerted by LH, as 
demonstrated in vitro, and estradiol, which increases via the cAMP/PKA-pathway together 
with receptor number. In fact, estradiol may be used as a marker for successful pregnancy 
outcome (339). The maintenance of large LHCGR numbers in the corpus luteum reasonably 
predisposes later, massive progesterone synthesis induced by LH and, in case of pregnancy, 
hCG. Thus, LH and hCG should ensure proper progesterone levels which, in turn, mediate 
events preparatory to and supportive of pregnancy. Indeed, women undergoing recurrent 
miscarriage may achieve better pregnancy outcomes through progesterone supplementation 
(340). These data illustrate the role of both LH and hCG in endometrial preparation and 
maintenance of corpus luteum through adequate steroid production. It is reasonable that 
endometrial preparation by LH addition in ART cycles may provide adequate stimuli leading 
to lower pregnancy loss (341), while hCG could not provide similar activity and leads to 
different effects in pregnancy outcomes (11). As the hormone of pregnancy, hCG exerts its 
specific functions during the first trimester, resulting in angiogenetic effects and increased 
progesterone synthesis. These roles are irreplaceable, as demonstrated by reports describing 
the association between recurrent miscarriage and mutations of the hCGβ-encoding genes, 
which impair signal transduction and alter the biochemical properties of the molecule (281). 
Notably, in women undergoing successful pregnancy, serum and urinary levels of the 
hormone are different, compared to those measured in the case of miscarriage (342). Thus, 
specific hCG functions and support of embryo development also depends on hormone levels. 
Cancer 
Since LH and hCG may activate intracellular signaling cascades regulating cell proliferation 
and anti-apoptotic events, it was suspected that they might retain tumorigenic potential and be 
involved in cancer formation via LHCGR-induced signals (343). As a matter of fact, mouse 
models revealed that tumorigenesis at gonadal and extra-gonadal sites is related to excessive 
gonadotropin levels (254). Similar conclusions are suggested by CGB gene mutations, 
leading to aberrant hCG production and linked to gestational trophoblastic neoplasia (344). 
An interesting case-report provided evidence of hCG-dependent tumorigenesis: a woman 
under chemotherapy due to metastatic renal cell carcinoma who became pregnant during the 
treatment break period developed a dramatic growth of the tumor (345). This event was 
consistent with hCG production and LHCGR expression in cancer cells, while clinical 
abortion coincided with rapid tumor regression, suggesting that the angiogenic potential of 
high hCG was proportional to hormone levels. On the other hand, the relationship between 
cancer cell growth and production of hCGβ and hCG-H molecules would be suspected (346), 
since they are the major isoforms produced over the first weeks of pregnancy. Their 
tumorigenic potential may rely on ERK1/2- and AKT-pathways, which is surprising since 
these pathways are preferentially activated by LH rather than hCG. Overall, 
hyperglycosylated hCG molecules were suspected to induce proliferative signals required to 
enhance maternal immune cell modulation, embryo implantation and trophoblast invasion at 
the early pregnancy stages (347). In vitro findings confirmed the proliferative potential of 
hCGβ and hCG-H (348). These data are consistent with the hypothesis that hCGβ and hCG-H 
exert different intracellular signaling than the “classical”, dimeric hCG (343), and that their 
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action should be focused on activation of cAMP/PKA-mediated steroidogenic signals (6,227) 
fundamental for massive progesterone production during pregnancy. This molecular 
mechanism could be the basis of a protective effect against breast cancer (349), since 
relatively high intracellular cAMP levels may trigger the activation of apoptotic processes in 
certain cell types (350,351), including breast cancer cells (352) and testicular germ cell 
tumors (162). Moreover, high LHCGR expression levels may result in increased sensitivity to 
hCG-induced pro-apoptotic signals, suggesting that receptor levels are a prognostic value, at 
least in some ovarian cancers (353). On the other hand, hCG steroidogenic potential may be 
transposed in vivo as increased production of estrogen metabolites and growth factors 
displaying pro-angiogenic and proliferative activity (354), thus indirectly inducing variable 
effects, depending on the enzymatic milieu of target cells. 
“Overload” of steroidogenic, LHCGR-induced signals might also be provided by 
excessive LH activity. The lesson of mouse models overexpressing human LH proves that 
gonadotropin tumorigenic potential is a result of hyperstimulated ovaries, which are induced 
to produce high estrogen levels (355). Similar results were observed in hCG-overexpressing 
mice (356), demonstrating that, in rodents, high levels of both human gonadotropins produces 
comparable steroid-dependent effects in vivo, as suggested using mouse Leydig cells in vitro 
(8). Interestingly, gonadectomy of certain mouse strains is linked to Lhr- and estrogen-
independent adrenal tumors, which are phenotypically different to those developed in mice 
overexpressing LH, hCG or Fshr (357,358), suggesting that the adrenal gland may be a target 
of gonadotropin action (359). These data are suggestive of molecular mechanisms putatively 
linking adrenal tumors and high LH levels encountered during human menopause. A 
gonadotropin-responsive adrenocortical adenoma was reported in a menopausal woman, 
featuring relatively high testosterone levels in response to stimulation of cancer cells by 
endogenous LH (360). Similar effects may arise in LHCGR-overexpressing adrenal tumors 
found in some cases involving menopausal and pregnant women (361). Large amounts of 
receptors would trigger an aberrant activation of the Wnt-pathway by binding endogenous 
gonadotropins, stimulating differentiation of adrenocortical cells, and similar tumorigenic 
effects may be due to activating LHCGR mutations in males, providing high basal cAMP and 
inositol phosphate levels (362). In this case, both excessive testosterone synthesis and 
proliferative signals may be linked to Leydig cell tumors as well as prostate cancer, and 
downregulation of the HPG axis by GnRH antagonists may be applied as clinical treatment to 
counteract aberrant cell growth (363). 
In conclusion, causality between gonadotropins and cancer is not sufficiently supported 
by the scientific literature. Tumorigenesis may rather be linked to the action of steroids, 
which, in certain cases, are synthesized by tumor cells and induce proliferative events. On the 
other hand, cancer cells may display aberrant transcription of gonadotropins and their 
receptor genes, as well as other hormones and receptors (364) such as steroids, GnRH, 
growth factors, etc. In particular, the presence of a specific receptor expression per se may 
not be indicative of cell function, since the opposite effects may depend on quantitative 
expression of GPCRs (210). Given the tumor-specific nature of the expression of these 
factors, the resulting effects are unpredictable. The complexity of tumor cell metabolism 
provides a unique picture which should be evaluated on a case-by-case basis, and specific 
treatments entrusted to clinicians’ decision. 
VII. Clinical applications 
Gonadotropins are clinically employed in both sexes when endogenous production is 
impaired, as in the case of HPG disruption. Indeed, in hypogonadotropic (e.g. secondary or 
central) hypogonadism, gonadotropin administration represents the most physiological 
therapeutic approach. The administration of steroids, i.e. estradiol/progesterone in women or 
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testosterone in men, is preferred in selected cases. However, when the physiological HPG 
activity is to be restored, and the direct stimulation of the gonads is necessary, gonadotropin 
administration becomes mandatory. This therapy consists of daily or weekly 
subcutaneous/intramuscular injections of biological compounds, more expensive than 
steroids and cumbersome for the patient. Despite these challenges, this is the only therapeutic 
approach, which can mimic the complex balance of gonadotropin stimulation of the gonad. 
Although the most frequent gonadotropin application is in controlled ovarian stimulation 
(COS) for ART, this approach remains largely empirical and not sustained by strong 
scientific evidence.  Moreover, the business related to this treatment makes the current 
pharmacological schemes for COS widely industry rather than science-driven. There was no 
real scientific interest in establishing the best gonadotropin combination in clinical practice 
during the last few decades. However, hypogonadotropic hypogonadism (HH), characterized 
by the lack of endogenous gonadotropin secretion, represents the best in vivo model to 
compare different actions of gonadotropins, evaluating their kinetics and efficacy. 
In this chapter, we assess the current LH/hCG biological compounds and their clinical 
applications. 
Urinary and recombinant preparations 
LH and hCG are both available as registered drugs (Table 4). Their biological activity (i.e. 
calibration) is evaluated by in vivo bioassays, assessing the gonadotropin effects in living rats 
or mice (236). The “Van Hell” bioassay is the standard method in pharmacopeia to assess 
gonadotropin bioactivity (165). This method, developed in the 1960s, is based on daily 
subcutaneous injection for 5 days of a fixed gonadotropin dose in 21-28 day-old immature 
male rats until the final measurement of seminal vescicles weight gain (165). Both LH and 
hCG are calibrated using the “Van Hell” method, comparing their bioactivity to an 
International Standard (365). This method shows two main limitations. First, the animal 
model used is unable to discriminate between LH and hCG. Second, this bioassay evaluates 
gonadotropin steroidogenic activity and not the full spectrum of molecular actions (366). 
Indeed, mouse Leydig cells were recently used in vitro to detect biological differences 
between LH and hCG. In addition to the qualitative differences previously demonstrated in 
human granulosa cells (6,228,229), LH and hCG resulted in quantitatively different early 
intracellular actions of cAMP/PKA pathways and steroidogenesis (8). These results suggest 
that the “Van Hell” method might not evaluate gonadotropin bioactivity correctly, and 
certainly not fully since it only evaluates testosterone dependent endpoints (8,367). Thus, the 
calibration of LH and hCG compounds by the “Van Hell” bioassay does not consider the 
differences in the molecular action described above. 
[TABLE 4]  
Historically, the first gonadotropin isolation dates back to the third decade of the last 
century, when two compounds, with FSH and LH activities, were extracted from the urine of 
pregnant and postmenopausal women and named Prolan A and B, respectively (368). Only in 
the 1950s were the early gonadotropin compounds produced, first from human pituitaries 
then from urine when the human menopausal gonadotropin (hMG) was purified from 
postmenopausal women (369). These first compounds showed a FSH:LH activity ratio of 1:1, 
ensured by both LH molecules and supplementation of hCG derived from the urine of 
pregnant women. However, a large amount of impurities was detected, consisting of LH 
subunits, growth factors, glycoproteins, binding proteins and immunoglobulins (370). All 
these residues caused high batch-to-batch variability and could influence hMG biological 
action, reducing efficacy and exposing patients to possible adverse events (370). The urinary 
purification process was subsequently improved, eliminating all residual extraneous 
activities, but leading to progressive LH loss. In order to maintain the FSH:LH ratio 1:1, LH 
activity was replaced by urinary hCG (371). Thus, in highly purified (HP)-hMG compounds, 
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the impurities percentages dropped to 30%. hCG molecules represent 95% of the remaining 
protein content (372). Hence, hMG compounds with highest purity were defined as those 
containing the lowest amount of LH and the highest hCG concentration (372). However, hCG 
molecules added to hMG are calibrated in vivo in rodents against an LH standard. Thus, the 
amount of hCG in the final compound is the number of molecules capable of producing a 
biological effect equivalent to that of the LH standard. This process depends largely on half-
life and does not consider the molecular differences between LH and hCG. Therefore, the 
number of hCG molecules in the final preparation could be significantly lower than the 
number of LH molecules needed to obtain the same biological action with a disequilibrium, 
in molar terms, between receptor and ligand. This concept must not be understated since the 
different number of LH/hCG molecules competing with the same number of receptors could 
be relevant in terms of LHCGR occupancy and activation (169). 
Overall, while FSH is easily obtained by urine purification, LH is lost during the 
chromatography steps, reducing the efficiency of obtaining urine-derived LH preparations. In 
contrast, u-hCG preparations were readily developed because of the abundance of hCG in the 
urine of pregnant women (373). Thus, urine-derived biological compounds containing LH 
alone were not available and until the advent of DNA technologies, only u-hCG compounds 
have been used to obtain LH activity in clinical practice. Recombinant DNA technologies led 
to the production of gonadotropins in CHO cell lines, with high rates of safety and 
consistency. Currently, six recombinant gonadotropins are available: follitropin α, follitropin 
β, follitropin γ (r-FSH), lutropin α (r-LH), choriogonadotropin α (r-hCG) and chorifollitropin 
α (374). r-LH and r-hCG possess greater purity as compared to the urine-derived 
counterparts, and consist of a mixture of isoforms exhibiting a high degree of glycosylation 
heterogeneity, structurally and biologically comparable to endogenous gonadotropins, with 
slight differences due to post-translational modifications (366).  
Alongside classical gonadotropins, recombinant DNA technology allows for the creation 
of new chimeric compounds, e.g. long acting FSH (chorifollitropin α) (375). In this case, the 
FSH β subunit was coupled to the carboxyl-terminal part (CTP) of the hCG β subunit 
(376,377). Chorifollitropin shows in vitro and in vivo pharmacological activity comparable to 
r-FSH, but with longer half-life (about 65 hours) (378). This in an interesting example of how 
DNA technologies could mix several gonadotropin features in the same compound. 
Different clinical effects: ovarian stimulation, luteal support and other aspects 
The gonadotropin administration in COS during ART is the current in vivo model in which 
the different clinical effects of biological compounds containing LH and hCG can be 
evaluated. In this setting, although a truly standardized approach does not exist, FSH 
administration is always provided to obtain multifollicular growth (379). In addition to this, 
LH or hCG administration may be added to support FSH action, mimicking the 
physiological, concerted action of LH and FSH. Indeed, LH physiologically regulates 
follicular growth, stimulating theca cell production of androgens, which, in turn, serve as a 
substrate for estradiol production in granulosa cells (380). In the late follicular phase, the 
estradiol rise acts through a positive feedback causing the LH surge needed for ovulation 
(381). Finally, LH stimulates progesterone production from the corpus luteum, which is then 
maintained by hCG if pregnancy occurs. To mimic this complex gonadotropin-mediated 
process during COS, regulatory agencies allow the addition of LH, hCG or hMG to FSH, 
since they are still considered equivalent in clinical terms. No specific guidelines are 
available to select which patient may benefit from and should be treated with a specific 
combination: the selection remains largely empirical, if nor arbitrary. 
In contrast, hCG is generally used at the end of the COS phase, to trigger final oocyte 
maturation. Physiologically, however, it is LH that is responsible for final follicular 
maturation and follicle rupture with oocyte expulsion from the follicle (382). Despite this 
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difference between COS protocols and physiology, mainly due to the historical availability of 
hCG but not of LH, the final ART outcome did not change when u-hCG or r-hCG were 
compared to LH (382). Thus, no specific evidence supports the use of LH instead of hCG for 
triggering ovulation. In 1979, the use of a GnRH agonist to induce an endogenous LH surge 
sufficient to trigger ovulation was proposed (383). This alternative to hCG was not exploited 
until the use of GnRH antagonists for pituitary down regulation in COS, with a shorter and 
reversible action compared to the agonists (384,385). Thus, under GnRH antagonists, the 
pituitary gland remains responsive and a single GnRH agonist bolus is sufficient to displace 
the antagonist, activate the receptor and induce the endogenous LH release, mimicking the 
physiological midcycle gonadotropin surge (383). This surge consists of a short ascending 
limb of about 4 hours and a long descending limb of about 20 hours (386). This pattern is 
slightly different from the physiological midcycle surge, which lasts 48 hours and shows 
three consecutive phases (387). Despite GnRH agonist triggering could be more 
physiological and could reduce the adverse event risk (388,389), neither large retrospective 
studies (390) nor randomized clinical trials (RCTs) (391,392) found differences between 
GnRH agonists and hCG for triggering ovulation. Thus, specific evidence favouring one or 
another ovulation trigger scheme are not available, considering the final ART outcome. In 
particular, specific hCG actions are obtained with this treatment, such as sustained 
progesterone production, angiogenesis promotion, blood flow and nutrition to the fetus (149), 
umbilical cord development and uterine growth synchronization (380). Thus, hCG 
substitution by LH or GnRH agonist for triggering results in the loss of all these essential 
hCG activities after fertilization. As a consequence, when GnRH agonist trigger is used, an 
appropriate luteal support with progesterone and estradiol should be considered (393). While 
this issue is not fully clarified and needs further investigation, it is established that luteal 
support with progesterone is used in all cycles. Some authors proposed a modified luteal 
support when GnRH agonist trigger is chosen, using hCG either in one, 1500 IU single bolus 
(394) or in repeated 250-500 IU boluses (395), or with LH addition (396). However, a recent 
meta-analysis showed that the GnRH agonist trigger use, together with a luteal support by LH 
activity, leads to similar ART outcomes compared to clinical protocols with hCG trigger 
(388). This analysis showed a notably high heterogeneity in the results, limiting its clinical 
significance. 
COS represents the best in vivo example in which gonadotropin combinations are used in 
pharmacological doses, although the various protocols are neither based on physiology nor on 
sound scientific evidences. Obviously, LH and hCG are interchangeable in this 
“unphysiological” context and it is surprising how well ART works in spite of sometimes 
disparate and “creative” stimulation protocols. It is difficult to draw physiological 
conclusions about LH and hCG from the supra physiological setting of COS. HH should 
represent a better model to understand the different efforts in vivo of LH and hCG, if they 
exist. 
Clinical experience with LH and hCG: the present and the future 
LH activity is needed in clinical practice in the management of both female and male 
hypogonadism when estrogen and androgen production should be stimulated through the 
direct action on theca and Leydig cells, respectively. Although both LH and hCG are 
currently commercially available, historically, only hCG has been used, as it was the only 
readily available LHCGR ligand. In theory, both LH and hCG might be used now in spite of 
the complete lack of scientific evidence in favor of one versus the other. This is true in many 
countries for female hypogonadism, but not in males, in whom only hCG administration is 
permitted by regulatory agencies. It is widely demonstrated that hCG is efficient at restoring 
eugonadism in HH men. Indeed, in the case of male hypogonadal hypogonadism, the 
standard therapeutic approach has been based on hCG administration since the 1950s (397). 
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In this setting, convincing evidence about the efficacy of hCG administration is available, 
considering different dosages and schemes, ranging from 1000 IU every other day (398) up to 
5000 IU two times weekly (399). However, the reason for hCG administration being 
preferred to LH in clinical practice resides in the historic availability of commercial 
preparations, rather than systematic, evidence-based demonstrations. Indeed, no clinical trials 
have compared LH to hCG in male HH, thus far. Only a single case report is available in the 
literature, comparing a daily low hCG dose (75 IU) to r-LH (75 IU daily) administration in a 
man with HH following surgery for a pituitary adenoma (234). In this man, either hCG or r-
LH restored eugonadism without exhibiting a significant difference. A careful comparison of 
the in vivo action of LH and hCG in HH men is needed. In 19 healthy men under pituitary 
suppression by a GnRH antagonist, it was demonstrated that a daily LH dose of 112.5 IU 
restored testosterone levels to the normal range (400). This trial showed that there were no 
differences when comparing bolus to pulsatile administration, suggesting that the 
physiological pulsatile LH secretion pattern is not strictly needed to obtain Leydig cell 
stimulation (400). These two examples indicate that low doses of LH may be sufficient to 
stimulate testicular androgen production, to an extent similar to that obtained by apparently 
much higher doses of hCG (5000 IU/weekly for hCG vs 787.5 IU/weekly for LH), revealing 
that the dosage of LH necessary to stimulate physiological testosterone production might be 
much lower than expected. If so, this would clearly indicate a differential action of LH and 
hCG in vivo, in human males. Clinical studies with LH in HH male are urgently needed to 
explore this. 
In women, the main LH clinical application remains COS during ART. Several trials 
evaluated different ART outcomes using LH instead of hCG to support follicular growth 
(Figure 5) (11). Despite their large number, these studies show high heterogeneity and low 
quality, hindering the development of standard protocols based on scientific evidence. Thus, 
the gonadotropin stimulation during COS, claimed to be “personalized” by ART doctors 
remains a peculiar example of personalized medicine, in that personalization is not based on 
selection of the appropriate stimulus according to objective criteria, but rather on the 
“personal” beliefs of the prescriber. This challenge is further complicated by the increasing 
number of young infertile couples seeking ART and the corresponding cost of gonadotropins 
and procedures, which leaves the pharmacological approach widely industry-driven. 
In this confusing setting, several clinicians proposed LH activity addition to FSH during 
COS. This relatively new combination is widely debated in the literature, in particular 
regarding poor responders and women of advanced age (401–403). Available evidence does 
not clearly support the hypothesis of increased pregnancy rates using LH combined with FSH 
in unselected women (404), and the number of published meta-analyses almost outweigh the 
number of RCTs available on this topic, suggesting the difficulty to design an objective meta-
analysis to identify the best COS approach, distinguishing the real benefit of one treatment 
compared to another (403). Apart from the paucity of adequately powered studies and the 
extremely high heterogeneity of treatments used, this topic is weakened by the heterogeneity 
of endpoints evaluated in RCTs (403). Indeed, the vast majority of RCTs, as well as of meta-
analyses, focused on the ART clinical outcome. However, when the effectiveness of LH/hCG 
addition is the topic of investigation, the first endpoint to be evaluated must be the ovarian 
response, i.e. the first measurable parameters of gonadotropin action. Pregnancy and live 
birth rates, on the contrary, are final results of ART and are influenced by an increasing 
number of factors (e.g. sperm contribution, endometrial receptivity and implantation, 
placenta, etc…). A recent meta-analysis combined the results available in the literature, 
considering all gonadotropin combinations and all ART outcomes, demonstrating that FSH 
alone obtains greater oocyte numbers compared to hMG or FSH + LH (11). The LH activity 
addition is useful to reduce the amount of FSH needed and to improve oocyte quality, but 
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only when LH is used rather than hCG. This could be a further suggestion that, by reducing 
the FSH doses used, FSH activity in granulosa cells is shifted from pro-apoptotic to 
proliferative pathways, like those activated by LH (200,228,229). Only 5 studies directly 
compared LH to hCG, however, none clearly reported the hCG dosage combined with FSH, 
thereby preventing any estimation of the real exposure of the ovary to LH/hCG in terms of 
molar relationship between LH or hCG and the LHCGR.  
With the limitation of the pharmacological rather that physiological setting, these results 
suggests that it is difficult to establish the correct amount of LH to be used in clinical 
practice, which might be different depending on the clinical setting (HH or COS) and gender. 
In addition, considering the difficulty of measuring in vivo LH bioactivity using approved 
bioassays, the debate remains fully open. The correct appraisal of the clinical application of 
LH should probably combine in vitro and in vivo demonstrations. 
[FIGURE 5] 
Complications of LH and hCG therapy 
In the evaluation of possible clinical applications of LH and hCG, adverse events must also 
be considered. The most relevant iatrogenic COS adverse event remains OHSS, which is the 
final result of an exaggerated ovarian response (405). It rarely occurs when ART is applied to 
unselected women (from 1 to 8%), but its incidence increases when high-risk women are 
treated (405). This risk is associated with low body mass index, young age, high estradiol 
serum levels, high interleukin concentrations, high vascular endothelial growth factor 
(VEGF) and renin-angiotensin system activation, although specific predictive parameters are 
not available so far (406). Moreover, either the elevated estradiol serum levels obtained at the 
day of ovulation or the large number of follicles developed during COS could predispose to 
OHSS (406). These OHSS predisposing conditions could be related to gonadotropin action 
and should be carefully evaluated to predict the occurrence of adverse ART events.  
hCG, rather than LH, is generally used to trigger ovulation. Besides differences at the 
molecular level, LH and hCG show different circulating half-lives (389). The sustained 
luteotropic activity induced by hCG could lead to side effects through the release of 
vasoactive substances (e.g. VEGF) and prostaglandins acting directly on the ovarian follicles. 
These direct and indirect effects could result in OHSS (389). Triggering ovulation with a 
GnRH agonist instead of a classical hCG bolus seemed to reduce OHSS risk (407,408). A 
recent meta-analysis claimed a reduced OHSS rate in GnRH agonist- compared to hCG-
triggered cycles, although no statistical significance was reached (388). These considerations 
confirm the lack of clear knowledge of OHSS pathophysiology. In order to enhance 
knowledge of underlying pathophysiological mechanisms and to reduce the incidence of this 
adverse event, the two different clinical OHSS presentations should be considered separately 
(405). First, early OHSS occurs within 9 days after hCG administration as a final, prolonged 
hCG effect on already stimulated ovaries. This OHSS clinical picture could probably benefit 
from the replacement of the hCG trigger by a GnRH agonist. Late OHSS occurs more than 10 
days after triggering, representing the ovarian response to the endogenous hCG rise after 
fertilization (405). This late complication does not benefit from hCG substitution and further 
research is needed to better understand this condition and its prevention.  
Alongside OHSS, other clinical COS complications must also be considered. Among 
these, the most frequent adverse effect is the cycle cancellation, which occurs in 11.5-17.4% 
of women of advanced age (409). This event leads to important socio-economic 
consequences due to the need to repeat COS, further exposing women to OHSS risk and 
increasing the economic burden. The main reason for cycle cancellation remains an 
inadequate response to gonadotropin stimulation. This probably results from both the lack of 
standardization in COS protocols and the high heterogeneity of clinical responses. The only 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
e 
R
ev
ie
w
s
Downloaded from https://academic.oup.com/edrv/advance-article-abstract/doi/10.1210/er.2018-00065/5036715
by Ombretta Malavasi user
on 19 July 2018
AD
VA
NC
E 
AR
TI
CL
E
Endocrine Reviews; Copyright 2018  DOI: 10.1210/er.2018-00065 
 
 
38
chance to reduce the cycle cancellation rate is a truly, evidence-based personalization of COS 
schemes, which requires rigorous clinical studies.  
In HH men, the only adverse event that must be considered during hCG/LH treatment is 
excessive serum testosterone levels, with possible negative effects on red blood cells, liver 
and prostate gland. However, this effect is the result of androgen action on sensitive tissues 
rather than a direct consequence of hCG administration. It will be interesting to explore 
whether HH treatment by LH rather than hCG will be able to reduce the rate of adverse 
events. Similar conclusions may be applied to pharmacological treatment of cryptorchidism. 
The pathology is identified by absence of one or both undescended testes to the scrotum and 
is linked to germ cell loss, infertility and increased testicular cancer risk (410). Descent of 
testes may be induced by hCG administration or by surgery. Interestingly, treatment of 
cryptorchidism with hCG was associated with germ cell apoptosis and impaired reproductive 
function in the adult (411). This effect is consistent with the cAMP/PKA-dependent pro-
apoptotic potential of hCG and might plausibly be dampened by administering LH instead of 
choriogonadotropin. However, the use of LH as a treatment for cryptorchidism has never 
been reported. 
VIII. Beyond reproduction: effects of hCG on thyroid and adrenal glands 
 Thyroid hormones and TSH are involved in metabolism and development regulation, 
and increasing evidence highlights a role for these molecules even in reproduction (412), 
revealing cross-talk between the gonadal and thyroid axes in vertebrates (413). High 
structural and biochemical similarities between the gonadotropins and TSH (414), as well as 
their receptors, underlie such interactions. Above all, the binding affinity of LHCGR and 
TSH receptor (TSHR) for their respective ligands relies on amino acidic residue at positions 
171-260 of the extracellular domains. These were considered to lead to chimeric receptors for 
hormone cross-interaction studies in the past (415). hCG-TSHR chimeras revealed 13-fold 
cAMP increases in transfected HEK293 cells and the effect was mimicked by high 
concentrations (1.0x104-105 ng/ml )(416) of hCG acting on wild-type TSHR in vitro, 
demonstrating cross-activation of the canonical cAMP/PKA-pathway (417), along with 
iodide uptake and tri-iodothyronine secretion in cultured human thyrocytes (418). An in vitro 
comparison between LH and hCG using a CHO cell line permanently expressing the TSHR 
cDNA (CHO-JP09 cells), revealed that LH is more potent than hCG in inducing intracellular 
cAMP increase and parallel line analysis demonstrated the overall equivalency of 1.0 µM 
hCG = 0.1 µM LH = 0.1x10-3 µM TSH (419). Interestingly, a mutant hCG lacking the CTP 
fragment displayed similar potency to LH, suggesting that the C-terminal peptide might act as 
a protective factor to prevent hyperthyroidism due to hCG cross-reactivity during pregnancy, 
when circulating concentrations of this hormone are extremely high. On the other hand, both 
LH and hCG are able to displace TSH bound to its receptor, thereby revealing an unexpected, 
about 162-fold greater thyrotropic activity in LH than hCG, equivalent to 44.0 and 0.3 µIU of 
TSH activity per 1.0 IU of LH and hCG, respectively (420). The fact that, in CHO-JP09 cells, 
enzymatic digestion of hCG resulted in deglycosylated and/or desialylated molecules with 
higher potency in activating cAMP compared to classical hCG (421), is suggestive of a 
plausible evolutionary conservation of the TSH dependence of thyroid function during the 
early weeks of pregnancy, and similar results were obtained with hCG preparations from 
patients with trophoblastic disease. These studies supported the concept of thyrotropic action 
of gonadotropins, especially hCG, which reaches relatively high serum levels during 
pregnancy or in patients affected by hCG-secreting tumors. It is indeed well known that the 
rise of hCG levels over the 9th-18th weeks of pregnancy matches the fall of TSH levels and 
sustains continuous thyroid hormone production (422): this likely depicts the dual function of 
hCG consisting of negative feedback exerted through thyroid hormones at the pituitary while 
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supporting thyroid function. These effects are emphasized during twin pregnancies, which 
features prolonged, higher hCG levels than single pregnancies, as well as more frequently 
increased free thyroxine and suppressed TSH levels (423). On the other hand, insufficient 
thyroid stimulation could result in low thyroid hormone levels and may lead to spontaneous 
abortion (424). Taken together, the metabolic regulation by thyroid hormones might be, in 
part, dependent on hCG during pregnancy and may be essential to support fetal development. 
 Since TSHR and thyroid hormone receptors are expressed in endometrial cells, their 
ligands might be involved in the physiological regulation of this tissue (425), although clear-
cut evidence remains to be found. Given the relatively high potency of LH in inducing 
TSHR-mediated cAMP production in vitro (419,420), a role for gonadotropins exerted at the 
level of the female reproductive system through the TSHR cannot be excluded. In fact, it is 
noteworthy that LH and TSH release by pituitary seem to be synchronized, at least during the 
menstrual cycle, largely measurable as a serum concentration peak of both hormones (426). 
Also, it is known that hypothyroidism before puberty leads to delayed sexual maturity, 
implying thyroid hormone action on gonadal functions (427). On the other hand, promiscuity 
of endocrine signals was demonstrated even in simple vertebrates, such as fish (29), 
suggesting that it is a conserved feature regulating certain physiological functions. It is not 
surprising that hypo- and hyperthyroidism are associated with menstrual disturbances, 
anovulation and subfertility in females (428). The cross-talk between thyroid and gonadal 
functions is anyway far from being thoroughly elucidated. The relatively recent discovery of 
thyrostimulin (429), a gonadotropin-like molecule acting on the TSHR, and considered the 
most ancestral glycoprotein hormone sheds new light on ovarian functioning. The production 
of thyrostimulin by oocytes has been described, suggesting that this molecule, rather than 
TSH, may act as a paracrine factor in the ovary by binding TSHR expressed in granulosa 
cells (430), where it would induce proliferative signals simultaneously activating 
cAMP/PKA-, ERK1/2- and AKT-pathways (431). Although suggestive, these findings should 
be confirmed by clinical evidence, required to understand the whole picture of the thyroid-
gonadal interaction. 
 Interaction between LH/hCG and the adrenal gland was described in healthy women 
during the menopausal transition, as an effect linked to increasing serum LH concentration, 
and during the first trimester of pregnancy, due to hCG production. The adrenal gland 
intriguingly shares a common developmental origin with gonadal cells (432): it is 
characterized by different types of cells secreting mainly glucocorticoids, as well as 
androgens and a small amount of estrogens. During the menopausal transition, the lack of 
progesterone negative feedback to the pituitary, occurring together with arrest of follicular 
maturation, results in increasing levels of LH molecules acting on LHCGR expressed in 
adrenal cortical cells (433). The adrenal gland response consists of the synthesis of 
pregnenolone metabolites obtained via the ∆5-steroidogenic pathway (434), mainly 
dehydroepiandrosterone and androstenediol (433), as well as cortisol (435). Most 
importantly, chronically elevated LH levels are suspected to be linked to an increased risk of 
adrenal tumors (435), even though further studies are required to elucidate the impact of LH 
on adrenal function. As a matter of fact, long-term elevated LH levels induce Lhr expression 
in mouse adrenal glands, a first step required for initiating cortical tumors (436), and it is 
possible that such an effect also occurs in humans (437). hCG action in the adrenal gland was 
mentioned in the “Pathophysiology of LH and hCG” chapter. In certain cases, increased hCG 
was suspected to be linked to adrenal LHCGR expression during pregnancy, resulting in high 
cortisol levels and transitory Cushing syndrome (298). However, hCG-stimulated synthesis of 
adrenal steroids is marginal in healthy women (438) and transient Cushing syndrome is a 
relatively rare event. 
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IX. Conclusions 
 The evolution of different glycoprotein hormones and their receptors accompanied the 
separation of distinct endocrine axes optimizing endocrine and metabolic functions, which 
developed independently in vertebrates. Inter-species ligand-hormone binding is possible, 
depending on the phylogenetic distance of the species, suggesting evolutionary conservation 
of key amino acid residues fundamental for the preservation of biochemical properties of the 
proteins. Intra-species interactions between endocrine axes are also possible, due to the 
common developmental origin of the hormone target cells, or as a means of optimizing 
certain metabolic functions. However, the complexity of the physiological mechanisms 
mediating placentation of certain mammals, such as equids and primates, required a more 
profound regulatory level, making the role of gonadotropins of pituitary and chorionic origin 
distinguishable. It is plausible that this complexity achieved its maximal expression in 
humans, where the largest number of genes encoding for LHβ/CGβ molecules likely evolved 
from a single ancestral one. Although these hormones may exist in more than one isoform 
and glycosylation variant, each displaying specific biochemical properties, their physiological 
roles may be separated according to specific functions required for gamete maturation and 
pregnancy support (Table 5). 
[TABLE 5] 
LH production is maintained in both males and females during the fertile age, when their 
functions depend on the specific enzymatic milieu of target cells. In women, the known 
androgenic role of LH is fulfilled by an overall flattened production of androstenedione by 
theca cells, as the major steroid serving as a substrate to be converted to the proliferative 
factor, estradiol, by granulosa cells under FSH stimulation. However, both progestational and 
proliferative LH-dependent effects have been shown to be relevant specifically in granulosa 
cells by in vitro experiments, revealing previously unknown regulatory molecular 
mechanisms suggesting that the aforementioned metabolic functions are fundamental for 
proper oocyte maturation. These roles are exerted through a fine-tuned modulation of the 
balance between the steroidogenic cAMP/PKA-pathway on the one hand, and 
proliferative/anti-apoptotic signals mediated through ERK1/2- and AKT-pathway activation 
on the other, thus exhibiting the capability of biased signaling mediated under synergistic 
modulation exerted by FSH. Hence, female folliculogenesis is assisted by two LH- and one 
FSH-target cells and characterized by both LHCGR and FSHR expression as a key factor for 
sustaining reproductive functions. This dual regulatory system might be involved in 
dampening signaling defects, resulting in overall mild pathological phenotypes, not 
necessarily leading to failed pubertal development or complete infertility, as in the case of 
PCOS. LH androgenizing function is maintained in the male counterpart of theca cells, the 
Leydig cell, where the steroidogenic pathway is driven towards testosterone synthesis as a 
major product required for male sexual development and reproduction. In this case, the lack 
of LH function leads to individuals with impaired sexual development, exacerbated by 
LHCGR inactivating mutations. Defective hCG signaling is naturally linked to pregnancy 
defects, mainly miscarriage, due to inappropriate progesterone synthesis, while excessive 
hCG signals may increase the risk of maternal, transitory Cushing syndrome or adrenal 
tumors. Trophoblast hCG may appear in women when the gonadal steroidogenic machinery 
is set to produce exclusively progesterone by luteinized ovarian cells, thus not requiring any 
discrimination between proliferative and steroidogenic signals. This was demonstrated by 
hCG treatment of granulosa cells in vitro, where hCG was not able to reproduce LH-specific 
proliferative signals but exhibited a relatively high steroidogenic potential. Even more so, LH 
and hCG treatment of mouse Leydig cells failed to reveal any qualitative differences, 
revealing the sex-specific nature of LH and hCG signaling. These data underline the 
significance of LH and hCG application to fertility treatments, especially in females, where 
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they are classically used as equivalents. This is an oversight caused by misinterpretation of 
clinical data provided by studies performed in the ART context, where LH- and hCG-specific 
effects are masked by those following the massive estrogen production induced to achieve 
multi-follicular development, not normally occurring in humans. The clinical comparison of 
LH and hCG in HH is needed to clarify many outstanding questions.  
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Figure 1. Genetic, structural and functional relationships between mammal LHβ an CGβ 
molecules. Mice have a unique Lh molecule encoded by a single Lhb gene. Mouse Lhβ acts 
through its receptor, which displays the exon 10-encoded portion at the hinge region, and 
regulates both gametogenesis and pregnancy. A CTP fragment appears as a product deriving 
from the equid Lhb gene, which is the source of a placental choriogonadotropin. While 
pituitary eLH regulates gametogenesis, eCG is specific for pregnancy in equids. However, 
they act on a common receptor with the exon 10-encoded sequence. The New World monkey 
C. jacchus has a peculiar LH/CG system: both gamete maturation and pregnancy are 
supported by a unique CGB gene encoding transcripts of both pituitary and placental origin 
and displaying the CTP fragment. Physiological functions are ensured by the LHR type II, 
lacking the exon 10-encoded portion, which binds the CGβ molecule in replacement of the 
missing LH. In humans, LH and hCG isoforms are encoded by specific genes belonging to a 
genetic cluster. However, pituitary LH lacking and placental hCG possessing a CTP appear 
as major products, specifically regulating gametogenesis and pregnancy, respectively. Both 
human LH and hCG act trough the same receptor displaying the amino acid sequence 
encoded by exon 10, which is fundamental for activating hormone-specific intracellular 
signaling. Deletion of LHCGR exon 10- encoded region leads to a truncated receptor capable 
of binding both LH and hCG, but resulting in impaired LH signaling and male infertility. 
Production of CGα, encoded by CGA genes, is required for proper dimer formation with β 
subunits, although CGα were not mentioned in the image. 
Figure 2. Differential free LHβ and hCGβ subunit release by somatotrope GH3 cells. Both 
hormones have an asparagine (N) residue, at position 13 of the amino acid chain (N13), 
which is glycosylated in the hCG molecule. N13 glycosylation prevents the disulfide-linked 
aggregation of β subunits and is involved in the maintenance of the correct folding in the 
absence of the α subunit. This mechanism may underlie the secretion of free hCGβ subunits 
occurring in pregnancy, when these peptides are produced in greater amounts than the α 
subunits, while free LHβ aggregates remain in the cytoplasm. |=conserved amino acid 
residues; :=different amino acid residues sharing similar biochemical properties; 
.=Biochemically different amino acid residues. 
Figure 3. Discrimination of LH- and hCG-mediated signaling by the LHCGR hinge region. 
Both hormones bind the extracellular domain of the receptor, but differently interact with the 
“U-shaped” portion of the hinge region. While hCG contacts the exon 10-encoded portion, 
LH spatial conformation leads to the interaction of the hormone with the extroflecting 
sTyr331 residue (upper panels). These ligand-receptor interactions result in LHCGR 
conformational changes associated with hormone-specific intracellular signaling. Exon 10 
deletion results in the shift of the sTyr residue impairing the interaction with LH, while a 
contact point of the “U-shaped” structure of the hinge region with hCG is maintained (lower 
panels). Thus, exon 10 deletion results in a truncated LHCGR unable to mediate proper LH 
signaling, albeit retaining both LH and hCG binding capability. 
Figure 4. Comparison of LH- and hCG-mediated signaling in the ovary and testis. At the 
mid-antral follicular phase, granulosa cells express both FSHR and LHCGR capable of 
forming homo/heterodimers, while theca cells express only LHCGR (upper panel). In 
granulosa cells, hCG displays a higher steroidogenic potential than LH, exerted via relatively 
high levels of cAMP/PKA-pathway activation, and this feature is potentiated in the presence 
of FSH. hCG action is exacerbated by massive production of progesterone, which is 
converted to androstenedione in the theca cell, while testosterone is a minor product in the 
gonads of the female. Androgens serve as a substrate for the aromatase enzyme, which 
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converts them to estrogens with high proliferative and anti-apoptotic potential. Intracellular 
cAMP increase is linked to pro-apoptotic stimuli, exacerbated in vitro by the absence of theca 
cell-derived substrate for estrogen synthesis. LH displays lower potency than hCG, in terms 
of cAMP/PKA-pathway activation, resulting in relatively low steroidogenic and pro-
apoptotic potential. LH signals are preferentially exerted via phosphorylation of ERK1/2 and 
AKT, following the recruitment of G protein and β-arrestins and resulting in 
proliferative/anti-apoptotic events. LH-specific signals are potentiated in the presence of 
FSH, which reasonably provides the main steroidogenic stimulus in granulosa cells. Theca 
cell androgenic potential increases together with the progression of antral follicle growth and 
amount of LHCGR expression, providing sufficient androstenedione to be converted to 
estradiol. To date, no in vitro studies have compared the action of LH and hCG in theca cells. 
Since Leydig cells are androgenic and exhibit LHCGR expression, they may be considered 
the male counterpart to theca cells. hCG is more potent than LH in inducing both the 
cAMP/PKA- and pERK1/2-pathway activation, but results in a qualitatively similar balance 
of stimulatory and inhibitory steroidogenic signals, as well as downstream testosterone 
synthesis. 
Figure 5. Overall model illustrating effects of LH versus hCG supplementation to FSH on 
ART outcomes. Scatter plots are obtained by meta-analysis (11) and indicate mean 
differences for each outcome evaluated. Data were interpolated using polynomial function. 
95% confidence intervals are not shown. Adapted under Creative Commons CC BY license 
from Santi D, Casarini L, Alviggi C, Simoni M. Efficacy of follicle-stimulating hormone 
(FSH) alone, FSH + leuteininzing hormone, human menopausal gonadotropin or FSH + 
human chorionic gonadotropin on assisted reproductive technology outcomes in the 
"personalized" medicine era: a meta-analysis. Front Endocrinol (Lausanne) 2017; 8:114. 
Table 1. Evolutionary and genetic differences between LH and hCG. 
Endpoint LH hCG Ref. 
Presence In all vertebrates In primates (CGs) (39) 
Evolutionary convergent molecules Callithrix jacchus pituitary CG Equid choriogonadotropin (eCG) (39,73) 
Number of genes in non-primates 1 0 (39) 
Number of genes in prosimian 1 0 (39) 
Number of genes in Macaca, Callicebus and Aotus  1 1-3 (39) 
Number of genes in C. jacchus  0 (one pseudogene) 1 (36,80) 
Number of genes in great apes 1 4-5 (39) 
Number of genes in Homo sapiens 1 6 (36,39) 
Number of pseudogenes in Homo sapiens 0 2 (32) 
Highest human gene sequence identity (92%) LHB (PMID NM_000894.2) CGB (GenBank BC041054.1) n.a. 
hCG is referred as the "classical" choriogonadotropin, except where indicated. n.a=not applicable/not available. 
Table 2. Molecular differences between LH and hCG. 
Endpoint LH hCG Ref. 
β amino acid chain length 121 amino acids 145 amino acids (99,102) 
Molecular weight ~26-32 KDa ~37 KDa (99,102) 
Highest human protein sequence identity (85%) LHβ (PMID NM_000894.2) CGβ5 (GenBank: AAI06724.1) n.a. 
LH/hCG-specific amino acid sequences Absence of CTP 28 amino acid CTP extension (71) 
Number of glycosylations 3 (two N-linked in the α 
subunit; one N-linked in the β 
subunit) 
8 (two N-linked in the α subunit; 
two N- and one O-linked in the β 
subunit) 
(133) 
Total isoforms and glycosylation variants 1 main molecule source of 
about thirty-nine isoforms 
chromatographically separated 
At least 9 main molecules 
("classical" hCG, hCG-H, nicked 
hCG, nicked hCG missing CTP, 
nicked hCG-H, asialo hCG, free 
hCGβ, nicked hCGβ, β-core 
molecule) source of an unknown 
number of variants 
(99,102) 
Molecular targets LHCGR LHCGR; Tβ-RII (criticized) (1,161,163) 
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Half-life 25 minutes 15-462 hours (102) 
hCG is referred as the "classical" choriogonadotropin, except where indicated. n.a=not applicable/not available. 
Table 3. Effective concentration for cAMP, pERK1/2 and pAKT activation, in primary 
mouse Leydig and human granulosa cells. 
Primary cell type Molecule cAMP EC50 pERK1/2 ECmax pAKT ECmax cAMP:pERK1/2 ratio Ref. 
human granulosa LH 530 ± 51 pM 100 pM 100 pM 5.3 (6) hCG 107 ± 14 pM 100 pM NA 1.1 (6) 
mouse Leydig LH 192 ± 54 pM 100 pM / 1.9 (8) hCG 18 ± 10 pM 10 pM / 1.8 (8) 
EC50=50% effective concentration; ECmax=min concentration maximally activating; NA=not activating; /=not 
assessed 
Table 4. Available drugs with LH and/or hCG activity, according to current regulatory 
agencies 
Preparation Provider Molecule Source Immunoreactivity 
Gonasi HP® IBSA Choriogonadotropin α  Urinary hCG 
Humegon® Organon Inc. Human menopausal gonadotropin Urinary FSH + LH + hCG 
Luveris® Merck KGaA Lutropin α Recombinant LH 
Menogon® Ferring Pharmaceuticals Human menopausal gonadotropin Urinary FSH + LH + hCG 
Menopur® Ferring Pharmaceuticals Human menopausal gonadotropin Urinary FSH + LH + hCG 
Ovitrelle® Merck KGaA Choriogonadotropin α Recombinant hCG 
Pergogreen® Serono Human menopausal gonadotropin Urinary FSH + LH + hCG 
Pergonal® Serono Human menopausal gonadotropin Urinary FSH + LH + hCG 
Pregnyl® MSD-Organon Choriogonadotropin α  Urinary hCG 
Table 5. Physiological differences between LH and hCG. 
Endpoint LH hCG Ref. 
Non-malignant source cell Pituitary gonadotrope cells Trophoblast and placenta; 
pituitary in very small amount 
 
Serum concentration in the fetus ~1/400th of the corresponding 
maternal serum concentrations 
~1/400th of the corresponding 
maternal serum concentrations 
 
Serum concentration in the prepubertal female 0.0-4.0 IU/l undetectable-2.3 IU/l  
Serum concentration in the prepubertal male 0.3-0.6 IU/l undetectable-0.8 IU/l  
Serum concentration in the pubertal female 0.3-31.0 IU/l undetectable-2.3 IU/l  
Serum concentration in the pubertal male  undetectable-0.8 IU/l  
Serum concentration in non-pregnant, fertile-age 
female 
0.0-0.2 mIU/dl (follicular 
phase); 20.0-105.0 IU/l (mid-
cycle peak); 0.4-20 IU/l (luteal 
phase) 
undetectable-2.3 IU/l  
Serum concentration in the fertile-age male 1.8-12.0 IU/l undetectable-0.8 IU/l  
Serum concetration in non-twin pregnancy n.a. 455.0-142584.0 IU/l (<10 weeks); 
3895.0-187852.0 (10-19 weeks); 
1542.0-86541.0 (>19 weeks) 
 
Serum concentration in post-menopausal women 15.0-63.0 IU/l undetectable-7.3 IU/l  
Physiological functions in the fertile-age female Androgen synthesis (mainly 
androstenedione) in theca cells, 
proliferative and progestinic 
signals in granulosa cells, 
support of antral follicle 
maturation, luteinization, 
transitory luteal support 
Progesterone production by 
corpus luteum, angiogenesis, 
cytotrophoblast differentiation, 
maternal immuno-suppressor, 
support of fetal growth and 
placentation, inhibition of uterine 
muscle contraction 
(103,257,397) 
Physiological functions in the fertile-age male Androgen synthesis (mainly 
testosterone) in Leydig cells, 
support of spermatogenesis 
n.a. (257,397) 
hCG is referred as the "classical" choriogonadotropin, except where indicated. n.a=not applicable/not available. 
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